Review Article

Bioactive Compounds from Kefir and Their Potential Benefits on Health: A Systematic Review and Meta-Analysis

Carla P. Vieira (1,2), Anisio Iuri L. S. Rosario (2,3), Carini A. Lelis (1,2), Bruna Samara S. Rekowski (3), Anna Paula A. Carvalho (1,2), Denes Kaic A. Rosário (1,2), Thaisa A. Elias (2), Marion P. Costa (3), Debora Foguel (4), and Carlos A. Conte-Junior (1,2,5)

1Center for Food Analysis (NAL), Technological Development Support Laboratory (LADETEC), Federal University of Rio de Janeiro (UFRJ), Cidade Universitária, Rio de Janeiro, RJ 21941-598, Brazil
2Laboratory of Advanced Analysis in Biochemistry and Molecular Biology (LAABBM), Department of Biochemistry, Federal University of Rio de Janeiro (UFRJ), Cidade Universitária, Rio de Janeiro, RJ 21941-909, Brazil
3Laboratory of Inspection and Technology of Milk and Derivatives, Escola de Medicina Veterinária e Zootecnia, Universidade Federal da Bahia, 40170-110 Bahia, Brazil
4Laboratory of Protein Aggregation and Amyloidosis, Instituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, 21941-590 Rio de Janeiro, Brazil
5Graduate Program in Sanitary Surveillance (PPGVS), National Institute of Health Quality Control (INCQS), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, RJ 21040-900, Brazil

Correspondence should be addressed to Carlos A. Conte-Junior; conte@iq.ufrj.br

Received 28 May 2021; Accepted 7 October 2021; Published 27 October 2021

Academic Editor: Demetrios Kouretas

Copyright © 2021 Carla P. Vieira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Despite evidence of health benefits from kefir administration, a systematic review with meta-analysis on bioactive compounds associated with these benefits is still absent in the literature. Kefir is fermented milk resulting from the metabolism of a complex microbiota in symbiosis. Recent researches have investigated the bioactive compounds responsible for the preventive and therapeutic effects attributed to kefir. However, differences in functional potential between industrial and artisanal kefir are still controversial. Firstly, we identified differences in the microbial composition among both types of kefir. Available evidence concerning the action of different bioactive compounds from kefir on health, both from in vitro and in vivo studies, was subsequently summarized to draw a primary conclusion of the dose and the intervention time for effect, the producer microorganisms, the precursor in the milk, and the action mechanism. Meta-analysis was performed to investigate the statistically significant differences ($P < 0.05$) between intervention and control and between both types of kefir for each health effect studied. In summary, the bioactive compounds more commonly reported were exopolysaccharides, including kefiran, bioactive peptides, and organic acids, especially lactic acid. Kefir bioactive compounds presented antimicrobial, anticancer, and immune-modulatory activities corroborated by the meta-analysis. However, clinical evidence is urgently needed to strengthen the practical applicability of these bioactive compounds. The mechanisms of their action were diverse, indicating that they can act by different signaling pathways. Still, industrial and artisanal kefir may differ regarding functional potential—OR of 8.56 (95% CI: 2.27–32.21, $P \leq 0.001$)—according to the observed health effect, which can be associated with differences in the microbial composition between both types of kefir.

1. Introduction

Fermentation of a matrix produces kefir. Milk is the matrix generally used, resulting in a beverage acidic, slightly alcoholic, and with a creamy consistency [1]. It results from milk fermentation by microorganisms that live in symbiosis in kefir grains. Kefir differs from other fermented milk because it is a metabolic result of a diversity of microorganisms. Lactose fermenting and nonfermenting yeast species (Kluyveromyces, Pichia, and Saccharomyces), with a predominance of lactic
acid bacteria (Lactobacillus, Lactococcus, Leuconostoc, and Streptococcus), besides acetic acid bacteria [2] make up the grain’s microbiota.

In recent years, there has been an increase in scientific research on kefir motivated by the association of beverage consumption with therapeutic effects [3]. Regular consumption of kefir has been associated to the reduction of severity of inflammatory bowel disease [4], antihypertensive effect [5], anticarcinogenic effect [6], increased insulin sensitivity [7], improved lipid profile [8], therapeutic effects on osteoporosis [9], and neurodegenerative disease [10]. The positive health effects have been related to the antioxidant capacity [11] and modulation of the intestinal microbiota [12] by the kefir drink. Bioactive compounds present in kefir, produced by microorganisms during fermentation and storage of beverage, have been attributed to these benefits; kefiran, exopolysaccharides, bioactive peptides, and organic acids are the bioactive compounds commonly implicated with the therapeutic potential of kefir [13–17]. However, there is still a need for a deeper discussion about the bioactive compounds present in the kefir drink [13] to distinguish them according to their therapeutic potential for each disease.

In addition, the possible difference in the functional potential between artisanal and industrial kefir is controversial in the literature. The use of kefir grains results in artisanal kefir [18], while previously selected starter culture of bacteria and yeast species leads to commercial or industrial kefir [19]. Some studies have reported artisanal kefir with greater therapeutic potential due to its greater microbiological diversity [20, 21]. In contrast, other studies have described industrial kefir as promising in treating diseases [22], while Ehbner et al. [23] have found no significant difference between both. In this context, a meta-analysis could be helpful to elucidate the inconsistencies observed between studies.

Thus, there have been some reports on bioactive compounds from kefir and health benefits in recent years. However, there is still a lack of an overview and in-depth approach in this research field, so a systematic review with meta-analysis will be relevant for this purpose. Therefore, it is necessary to summarize the bioactive compounds from kefir produced by different microorganisms that make up its microbiota, their beneficial effects, action mechanisms, and their precursors in the milk. Based on this knowledge, it will be possible to provide a theoretical basis for developing functional formulations by the food industry to prevent specific diseases. In addition, the pharmaceutical industry may prepare formulations with therapeutic potential from bioactive compounds isolated from kefir. In this scenario, this review summarized the antimicrobial, antioxidant, immune-modulatory, gut microbiota-modulatory, anticancer, antosteoporosis, antihypertensive, antidiabetic, and lipid profile-modulatory role of the bioactive compounds from milk’s kefir. Prevention and treatment of neurodegenerative diseases also were covered. The functional differences between both types of kefir finished this review.

2. Methods

2.1. Focus Questions. The development of the question was according to the population, intervention, comparison, and outcome (PICO) method. The questions formulated were as follows: What are the bioactive compounds in milk kefir and their producing microorganisms? What are the precursors of these bioactive compounds in kefir? Do bioactive compounds differ in terms of concentration and intervention time to obtain the same effect on health? Is artisanal kefir drink more functional than the one produced industrially?

2.2. Data Collection Process and Eligibility Criteria. Two authors (C.P.V and A.P.A.C) independently conducted the preliminary selection of identified abstracts and titles of research articles published in English; we removed the time filter not to limit the number of manuscript resulting. Thus, the initial screening publications covered the period from 1986 to 2021. Abstracts were then removed in this initial screening if the papers did not investigate any of the following health aspects: antimicrobial activity, antioxidant activity, effect on cancer, neurodegenerative diseases, lipid profile, blood pressure, plasma glucose, gut microbiota modulation, inflammation, and osteoporosis both in vitro, in situ, in vivo animal, and human clinical trials. The criterion used to choose these specific health benefits was that they had been the most investigated in the scientific literature in the last two decades [24–26]. Papers about nonmilk kefir were excluded, including editorials, letters, reviews, commentaries, monographs, preprints, and Ph.D. thesis. Based on the entire reading of the paper, all studies included in the present work were controlled experiments and with a quantitative approach for data analysis. Only studies in which it was possible to determine the bioactive compounds responsible for the observed health effect were included. Studies addressing the microbial composition of kefir grains or starter culture of milk kefir were also included. Some studies considered essential to compose the present work such as those that address conventional therapies, recent reviews on the effect of kefir, and pathology of the diseases studied that was not included in any of the research bases were added to compose our introduction and discussion.

Finally, we summarized information about the type of kefir (artisanal or industrial) from which the bioactive compound was derived, the study model, the definition of the bioactive compound, and its effects compared to the control treatment. The results were reported in agreement with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement.

2.3. Information Sources. Our search protocol strategy used search strings constructed and adapted for five electronic databases: Science Direct, Pubmed, Embase, Web of Science, and Scopus. The initial screening process was conducted from February 2021 to March 2021. Also, directed searching was carried out by checking the reference lists of relevant articles. The research questions were used to summarize the search strings through which the manuscripts were recovered. The string was based on predetermined groups of keywords related to microbial composition of artisanal
and industrial milk kefir, bioactive compounds in the milk kefir, and their effect on health, as follows:

1. Search Component 1. microorganisms OR "microbial composition" OR "kefir grains" OR "starter culture" AND "milk kefir"
2. Search Component 2. "bioactive compounds" OR "functional compounds" AND "milk kefir"
3. Search Component 3. "health benefits" OR "health effects" AND "milk kefir"

2.4. Risk of Bias Assessment. Possible sources of bias include eligibility criteria, the impact of missing data, missing primary results, chosen database, chosen language (English), and article type selected for our review.

2.5. Meta-Analysis. Two authors (A.I.L.S.R and D.K.A.R) to conduct the meta-analysis extracted data from the included articles. Any inconsistency in retrieved data was solved by discussion. In vitro, in situ, and in vivo papers were pooled for examination. From every publication, each different outcome point was extracted as an independent study. Then, we investigated a statistically significant difference between intervention and control. However, only health effects with an appropriate number of studies were included in the meta-analysis: antimicrobial (including eight groups of microorganisms, totaling 182 in vitro and in situ studies from 15 papers), antioxidant (149 in vitro and in situ studies included in 7 articles), anticancer (44 in vitro studies comprising five publications), immune modulation (271 in vitro and in vivo studies from 11 papers), and microbiota modulation (40 in vitro and in vivo studies retrieved from 5 publications) effects.

The analyses were conducted evaluating the presence or absence of health benefits for the different outcomes. The definitions of presence/lack of action varied across publications, as different methodologies were used on the selected studies. In this case, the resolution was directed by three authors based on the specific outcome. For example, considering antimicrobial research, if a result was expressed in log UFC, decreasing log UFC by kefir treatment was deemed "presence of action." Similarly, if a study result was defined as an inhibition zone, reducing zone size (mm) by kefir treatment was considered a "lack of action".

In addition, to measure the heterogeneity among studies, I^2 test was used. The I^2 assumes the null hypothesis that all the studies are homogeneous or that each study is measuring an identical effect so that a P value tests this hypothesis. In this scenario, the I^2 statistic describes the percentage of variation across studies due to inconsistency (heterogeneity) rather than sampling error (chance). A significance level of 0.05 was used herein. Studies with I^2 ≤ 50% were considered homogenous. The I^2 was quantified as follows [27]:

\[ I^2 (%) = \left( \frac{Q - d_f}{Q} \right) \times 100, \]  

where I^2 is the inconsistency across studies, Q is the Cochran’s heterogeneity statistic, and d_f is the degrees of freedom.

Subsequently, functional differences between artisanal and industrial kefir were investigated for health effects. Both types of kefir were tested: antimicrobial (182 in vitro and in situ studies) and antioxidant activity (149 in vitro and in situ studies). Then, studies were analyzed to compare the health effects of consuming artisanal kefir drinks rather than the industrial variety, evaluated by odds ratio (OR) and corresponding 95% confidence intervals (CIs). All analyses were performed using Review Manager 5.4 (Cochrane Collaboration, London, UK).

3. Results

3.1. Literature Search. There were 451 articles identified at Web of Science, 242 at Embase, 180 at Scopus, 107 at Pubmed, and 37 at Science Direct. Still, 8 articles were manually identified by other sources for addition of effect on neurodegenerative disease. Of these, 333 were duplicates or triplicates and were excluded, with 692 papers remaining. After reading the titles and abstracts, 263 papers were selected for the full read, but only 88 met the eligibility criteria (Figure 1). Among the articles read in full, the main reasons for exclusion were as follows: nonidentification of the bioactive compound (n = 112) and uncontrolled experiments (n = 23). This highlights the need for experiments with a more elaborate experimental design, as well as that identify the bioactive compound responsible for the health effects observed due to the use of kefir.

3.2. Meta-Analysis: Study Selection and Characteristics. Data extraction for meta-analysis consisted of 45 papers. Studies were conducted in Argentina, Brazil, Canada, China, Egypt, Iran, Italy, Japan, Malaysia, South Korea, Thailand, Taiwan, Turkey, the United Kingdom, and the United States of America. The publication year of studies ranged from 2005 to 2021. The concentration of kefir used in the studies varied between 0.01 and 1000 mg/mL. The interventions lasted between 0.5 and 1344 hours.

3.3. Structure and Microorganisms of the Kefir Grains. Kefir is a beverage commonly produced from milk and involves a complex fermentative process from the microbiological diversity in "kefir grains" [28]. Typically, kefir grains are inoculated into milk in proportions of 5% to 10% [29], which gives characteristics such as a creamy fermented milk with a slightly acidic taste depending on the starter culture and mixture of the inoculated microorganisms [1].

The diversity of the "kefir grains" embraces numerous symbiotic interactions between lactic acid bacteria (LAB), acetic acid bacteria, mycelial fungi, and yeasts [2], resulting in an acidic and alcoholic fermentation [30]. These microorganisms present in kefir are interspersed in a matrix composed of proteins and polysaccharides [31]. Macroscopically, this matrix can be characterized as solid, cauliflower-like grains viscous and firm consistency, with a color that varies from white to yellowish [32, 33].
According to Khokhlacheva et al. [34], the consortium between microorganisms that evolves an adaptive capacity and enzymatic activity is the key mechanism for their development and survival in milk kefir. In kefir grains, the lactic acid bacteria (LAB) usually present greater levels when compared with acetic acid bacteria. This composition presents itself dynamically and generally changes according to the fermentation time, where the dominance of *Lactobacillus kefiranofaciens* can be observed in the early stages of fermentation, giving rise to the most prominent growth of *Leuconostoc mesenteroides* in the final stages of the process [35]. Several studies around the world are aimed at determining the composition of kefir microbiota (Table 1) since it varies according to geographic, climatic, and cultural factors [33, 36].

The inoculated kefir grains ferment the artisanal kefir [18], while a previously selected starter culture of bacteria and yeast species results in commercial or industrial kefir [19]. According to Table 1, although the *Lactobacillus* and *Lactococcus* genera predominate in both types of kefir, *Enterococcus* was not reported in industrial kefir. Another important aspect can be pointed out in industrial kefir by commercial species not commonly found in artisanal kefir: *Saccharomyces boulardii, Lactobacillus lactis, Bifidobacterium lactis, Bifidobacterium longum, Bifidobacterium breve,* and *Lactobacillus reuteri*. Korsak et al. [29] corroborated these findings, reporting that industrial kefir is typically composed of selected cultures and conventionally used in dairy products.

Concerning fungal composition, although both types of kefir have presented common species, such as *Saccharomyces cerevisiae, Kluyveromyces marxianus,* and *Kazachstania unispora,* the fungal diversity in artisanal kefir was dramatically greater. In addition, *Kazachstania exigua,* *Kazachstania turicensis,* and *Saccharomyces florentinus* were reported only in industrial kefir (Table 1). Other differences between both kefirs include differences in efficiency under conditions of nutrient competition [41], location and adhesion of microorganisms in the structure of kefir grains, or even different abilities of species to grow in milk [18].

However, more microbiota characterization from artisanal and industrial kefir is necessary to define the microbial...
| Type of kefir     | Microbial diversity                                                                                                                                                                                                 | Source of kefir culture                                                                 | References                                      |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------------------------|
| **Artisanal**    | A. fabarum, A. okinawensis, A. orientalis, Enterococcus durans, Kz. unispora, Kl. marxianus, Lb. doliivorans, Lb. kefiri, Lb. kefriofaciens, Lb. otakiensts, Lb. paracasei, Lc. lactis, Sc. cerevisiae, A. orleanensis, A. pasteurianus, Acidocella aluminiiidurans, Gluconobacter morbifer, Lb. acidophilus, Lb. apis, Lb. casei, Lb. crispatus, Lb. delbrueckii, Lb. gigeriorum, Lb. helveticus, Lb. kefriofaciens, Lb. paracasei, Lb. rhamnosus, Lb. ultunensis, Lc. lactis, Lent. Kefri, Ln. mesenteroides, Streptococcus thermophilus | Chile, Argentina, Malaysia, Germany, South Korea, Ireland, United Kingdom, Italy, Canada, Germany | Marsh et al., 2013 [33]; Purutoglu et al., 2020 [40] |
| **Industrial**   | Aspergillus amstelodam, Cordyceps bassiana, Fusarium solani, Lb. casei, Lb. kefriofaciens, Lb. kefri, Lb. mali, Lb. paracasei, Lb. satsumensis, Lc. lactis, Lc. lactis ssp. cremoris, Lc. lactis ssp. lactis, Ln. mesenteroides, Enterococcus durans, Lb. kefri, Lc. lactis, Ln. mesenteroides subsp. dextranicum, Lactobacillus sp., Lb. delbrueckii, Lb. kefri, Lb. paracasei, Lb. plantarum, Lb. sakei, Lc. lactis, Ln. gelidum, Ln. mesenteroides, Pediococcus pentosaceus, Cryptococcus sp. vega, Cyberlindnera jadinii, Davidiella tassiana, Dekkera bruxellensis, Dioszegia hungarica, Eurotium amstelodami, Ganoderma lucidum, Heterobasidion annosum, Kz. barnetti, Kz. unispora, Kl. marxianus, Malassezia pachydermatis, Microdochium nivale, Naumovozyma Castelli, Penicillium sp. vega, Peziza campestres, Pichia fermentans, Pichia kudriavzevii, Sc. cerevisiae, Teratosphaeria knoxdaviesii, Wallemia sebi, Zygosaccharomyces lentus | Brazil, Taiwan, Russia, Ireland, United Kingdom, United States, Spain, France, Italy, Canada, Germany | Brasiel et al., 2021 [37]; Leite et al., 2015 [32]; Vieira et al., 2017 [38]; Zanirati et al., 2015 [36]; Khokhlacheva et al. 2015 [34]; Mantzourani et al., 2019 [39] |
similarities and particularities between these two types of milk kefir. This characterization is highly relevant since the beverage’s bioactive compound profile is closely related to the producing microorganisms present [42, 43]. The use of kefir grains in the artisanal beverage is correlated to higher counts in the final product and remarkable survival during passage through the gastrointestinal tract, proving significant probiotic properties compared to industrial cultures [42]. Thus, the analysis proposed here may justify possible functional differences between both types of kefir.

Kefir grain’s microorganisms can present the ability to produce bioactive compounds during the fermentation and storage of kefir beverages. Consistently, from 48 strains isolated from Russian kefir grains, ten species of Lactobacillus sp. were recognized with probiotic potential [39]. Some yeast strains, such as Saccharomyces cerevisiae KU200284, present double importance: a starter culture and a probiotic [44]. In Korean kefir, the acetic acid bacterial strain Acetobacter fabarum DH1801 had viability as a functional starter with food preservative mechanisms and the potential as a probiotic agent [45]. In addition, the species of LAB has a fundamental role in the formation of exopolysaccharide (EPS), which is a significant bioactive compound in kefir [37]. In this scenario, the Lactobacillus kefarifonaciens is considered the main piece in the formation of kefir grains [18] since its genes demonstrate a great capacity to produce exopolysaccharides (such as kefiran) which make up the structure of the kefir grain [43]. Similarly, Lactococcus lactis ssp. cremoris MRS 47 does found for Vieira et al. [38] to be capable of producing conjugated linoleic acid (CLA), a bioactive compound, from milk fat.

3.4. Bioactive Compounds from Kefir and Their Effects on Health

3.4.1. Antimicrobial Activity. The antimicrobial activity of kefir was mainly attributed to exopolysaccharides (EPSs), specially kefiran, and organic acids, especially lactic acid. However, bioactive peptides with antimicrobial activity have also been identified (Table 2).

Regarding the producing microorganisms, kefiran and EPS were produced by Lactobacillus kefarifonaciens, while bioactive peptides were synthesized by Lactobacillus paracasei, species belonging to the Lactococcus genus and yeast. Biofilms and S-layer proteins, turn on, were produced by Lactobacillus plantarum and Lactobacillus kefir, respectively (Table 2). It demonstrates that microorganisms of the Lactobacillus genus are relevant for the production of bioactive compounds with antimicrobial activity in kefir. In addition, among the 18 articles selected from the systematic review addressing the antimicrobial effect of the compounds, only 1 of them investigated the precursor of the compound in milk; thus, the investigation of the precursors of antimicrobial compounds in kefir is currently necessary. In vitro antimicrobial activity against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, Bacillus cereus, Bacillus subtilis, and Staphylococcus aureus was attributed to bioactive peptides produced from β-casein, k-casein, αs1-casein, and αs2-casein present in the milk [64]. Kefiran has demonstrated an antimicrobial effect for Streptococcus faecalis, Pseudomonas aeruginosa, Salmonella typhi, Bacillus subtilis, Bacillus cereus, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Streptococcus faecalis, and Fusarium graminearum [61, 69, 71]. In addition, kefiran also had action on fungi (Aspergillus flavus AH3) producing aflatoxins; a decrease from 100% to 33.3% of aflatoxin B1 production accompanied a decline in the mycelial dry weights [71]. Still, kefiran presented a more dramatic antimicrobial effect on E. coli than S. aureus, which can be attributed to the peptidoglycan in the cell wall of the latter. Peptidoglycan, in turn, hinders the diffusion of the antimicrobial through the cell. In addition, reports suggest that kefiran can reduce the concentration of antibiotics needed to obtain the antimicrobial effect, as illustrated by its synergism with ciprofloxacin [69]. It is interesting since extended administration of ciprofloxacin results in gastric and intestinal side effects [69].

Still, given the promising results of kefiran as a natural antimicrobial potential, its extraction methods from kefir have also been studied to maximize its antimicrobial effects.

Table 1: Continued.

| Type of kefir | Microbial diversity | Source of kefir culture | References |
|--------------|---------------------|-------------------------|------------|
| Artisanal and industrial | A. syzygii, Alternaria tenuissima, Bacillus sporothermodurans, Didymella negriana, Filobasidium magnus, Hanseniaspora thailandica, Kl. Marxivans, Kz. unispora, Lb. Kefranofaciens, Lb. parakefi, Lb. plantarum Lc. lactis, Lc. pseudoemseroides, Sc cerevisiae, Pichia manshurica, Pichia orientalis, Pichia fermentans, Torulaspora delbruexii Wickerhamiella pararugas | Bosnia and Herzegovina | Garofalo et al., 2020 [18] |
| | Lactococcus keflranofaciens | Belgium | Korsak et al., 2015 [29] |

A.: Acetobacter; Bif.: Bifidobacterium; Kl.: Kluyveromyces; Kz.: Kazachstania; Lb.: Lactobacillus; Lc.: Lactococcus; Ln.: Leuconostoc; Sc.: Saccharomyces.
Table 2: Effect and conditions of intervention with kefir bioactive compounds for different health benefits.

| Health effect                      | Model/participants                                      | Bioactive compound          | MO<sup>1</sup> | Concentration tested | Intervention time | Effect tested/ condition/ bioactive compound concentration | Effect compared to control | Action mechanism                                                                 | Reference |
|------------------------------------|----------------------------------------------------------|-----------------------------|----------------|----------------------|-------------------|-------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------|-----------|
| Anticarcinogenic                    | In vitro: MTT assay of MCF7 human breast cancer cell line | Kefirran                    | -             | 50 to 4000 μg/mL     | 48 h              | Cell viability                                             | ↓ up to 45%                | Upregulates the expression of apoptosis-related genes (Cyto-c, BAX, BAD, caspase 3, caspase 8, and caspase 9) in HT-29 cells | [46]      |
|                                    | In vitro: MTT assay of HT-29 human colon cancer cell line | Exopolysaccharide MSR01     | Lactobacillus kefir MSR101 | 50 to 400 μg/mL     | 24 h              | Cell viability                                             | ↓ up to 55.9%               | -                                                                                | [47]      |
|                                    | In vitro: MTT assay of HepG2 human hepatocellular carcinoma cell line and HeLa human cervical carcinoma cell line | Kefirran                    | Lactobacillus kefrnanofaciens | 15.6 to 1000 μg/mL   | 24 h              | Cell viability of HeLa cells                              | ↓ up to 72%                 | Adversely affected the morphological characteristics of HeLa and HepG2 carcinoma cell lines | [48]      |
|                                    | In vitro: fecal water-induced DNA damage assay in HT-29 human colon cancer cell line | Lactic and acetic acids     | -             | 20 to 200 μL/mL (preincubation) | 30 min           | DNA damage                                                 | ↓ 20%                     | Antioxidant activity                                                              | [49]      |
|                                    | In vitro: cell nuclei counting assay of MCF7-E3 human breast cancer estrogen-sensitive cells | Bioactive peptides          | -             | 0.31 to 10% (v/v) (incubation) | 6 days           | Cell number                                                | ↑ up to 88%                 | -                                                                                | [15]      |
| Anti-inflammatory                   | In vitro: DSS-induced acute colitis model in male wild-type C57BL/6 mice; chronic colitis model aggravated by Piroxicam in IL10<sup>-/-</sup> C57BL/6 mice | Extracellular vesicles (PRCC-1301 EVs) | Lactobacillus kefrgranum PRCC-1301 | 0.03 and 3 mg/kg bw/day | Acute colitis: from 2 days before administration of DSS to 5 days | Body weight, Colon length (3 mg/kg bw) | ↓ 116% | Promoting the intestinal barrier integrity through the expression of occlusion proteins (ZO-1, claudin-1, and occludin) in colon epithelial cells and inhibition of the NF-κB signaling pathway in the distal and proximal colon in an acute colitis model | [50]      |
|                                    | In vitro: RAW264.7 cell line (murine macrophages) | Exopolysaccharide R-17-EPS  | Lactobacillus pentosus LZ-R17 | 50 to 400 μg/mL     | 24 h              | Acute colitis, Chronic colitis: from 14<sup>th</sup> to 28<sup>th</sup> day (Piroxicam from day 0 to day 14) | Body weight, Colon length (3 mg/kg bw) | ↓ 29.6% | Histological score, Chronic colitis: from 14<sup>th</sup> to 28<sup>th</sup> day (Piroxicam from day 0 to day 14) | [51]      |
| Health effect | Model/participants | Bioactive compound | MO | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|-------------------|----|----------------------|------------------|--------------------------------------------------------|--------------------------|----------------|-----------|
| **In vitro**: DSS-induced acute colitis model in Caco-2 cell line cultures (human intestinal epithelial cells) | Extracellular vesicles | *Lactobacillus kefir* | PRCC-1301 | 100 μg/mL | 6 h | 100 to 200 μg/mL IL-6 | up to 10.2% | - | Kang et al. (2020) [50] |
| | | | | | | 50 to 200 μg/mL IL-1β | up to 16.7% | - | |
| | | | | | | 400 μg/mL IL-10 | ↓ 9.5% | - | |
| | | | | | | 100 to 200 μg/mL 50 μg/mL | Without effect | - | |
| | | | | | | Cytokine gene expression: IL-2 | ↑ up to 19% | - | |
| | | | | | | IL-8 | ↑ up to 19% | - | |
| | | | | | | TNF-α | ↑ up to 19% | - | |
| | | | | | | Macrophage cell viability | ↑ up to 19% | - | |
| | | | | | | Phagocytosis index | ↑ up to 19% | - | |
| | | | | | | Acid phosphatase activity | ↑ up to 19% | - | |
| | | | | | | NO production TNF-α | ↑ up to 19% | - | |
| | | | | | | 50 μg/mL | ↑ up to 19% | - | |
| | | | | | | 100 to 200 μg/mL 400 μg/mL | Without effect | - | |
| | | | | | | IL-6 | ↑ up to 19% | - | |
| | | | | | | IL-1β | ↑ up to 19% | - | |
| | | | | | | 100 and 200 μg/mL | ↑ up to 19% | - | |
| | | | | | | 50 and 400 μg/mL IL-10 | ↑ up to 19% | - | |
| | | | | | | 50 to 200 μg/mL 100 μg/mL IL-6 | ↑ up to 19% | - | |
| | | | | | | IL-6 | ↑ up to 19% | - | |
| | | | | | | 500 to 4000 μg/mL PBMC viability: 24 h | ↑ up to 19% | - | |
| **In vitro**: RAW264.7 cell line (murine macrophages) | Exopolysaccharide (R-5-EPS) | *Lactobacillus helveticus* | RZ-5 from Tibetan kefir | 50 to 400 μg/mL | 24 h | 1000 and 5000 μg/mL 220 ng/L | ↑ up to 25.5% | - | Jenab et al. (2020) [46] |
| | | | | | | 400 μg/mL 270 ng/L | ↑ up to 25.5% | - | |
| | | | | | | 24 h, 48 h, and 96 h | ↑ up to 25.5% | - | |
| | | | | | | 500 to 4000 μg/mL | ↑ up to 25.5% | - | |
Table 2: Continued.

| Health effect | Model/participants | Bioactive compound | MO$^1$ | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|--------------------|--------|----------------------|------------------|----------------------------------------------------------|---------------------------|----------------|-----------|
| In vitro: TNF-α-induced intestinal inflammation model in Caco-2 cell line | Extracellular vesicles (80 to 400 nm) | Lactobacillus kefir, Lactobacillus kefiranofaciens, Lactobacillus kefranogranum | $1 \times 10^7$ extracellular vesicles/mL (A strain mix ratio: 1 : 1) | 24 h | 500 to 1000 μg/mL | Without effect |  |  | [53] |
| In vitro: a cell-free system containing sodium nitroprusside (10 mM) | Kefiran | - | 5000 to 10,000 μg/mL | 2.5 h | 2000 to 4000 μg/mL | ↑ up to 200% |  |  |  | [53] |
| In vitro: FliC-induced intestinal inflammation model in Caco-2 cell line | Exopolysaccharide | Lactobacillus paraasai CIDCA 8313, CIDCA 83123, and CIDCA 83124 strains | $3 \times 10^7$ and $3 \times 10^10$ extracellular vesicles/head/day (A strain mix ratio: 1 : 1 : 1) | 10 days | Promoter induction: CCL20 | ↑ up to 55% |  |  | [13] |
| In vivo: TNBS-induced inflammatory bowel disease in Balb/c mice | Extracellular vesicles | Lactobacillus kefir, Lactobacillus kefiranofaciens, and Lactobacillus kefranogranum | - | 1 h (preincubation) | Hyaluronidase inhibition | ↓ up to 35% | Blocking MPO activation in mouse serum | Seo et al. (2018) [53] |
| In vitro: cell-free system | Polysaccharide extract | - | 5000 μg/mL | 72 h | Lactate - 100 mM | ↑ up to 12.5% | ↑ up to 75% | ↑ up to 10% | [55] |
| In vitro: intestinal inflammation model in Caco-2 cell line induced by IL-1β, TNF-α, or FliC | Lactate | - | 100 mM | 30 min (preincubation) | FliC-induced IL-1β-induced TNF-α-induced Secretion | ↑ up to 78% | Inhibition of the NF-κB signaling pathway | [56] |
| In vitro: peritoneal macrophages isolated from six-week Balb/c female mice | Protein (molecular mass > 30 kDa) | Lactobacillus kefiranofaciens M1 | 5 μL of kefir supernatant/mL | 24 h | Promoter inhibition CCL20 | ↑ up to 1000% | ↑ up to 700% | ↑ up to 130% | [57] |
| In vitro: Six- to 8-week-old BALB/c female mice | Kefiran | Lactobacillus kefiranofaciens | 100 mg/kg bw/day | 2, 5, or 7 days | Small intestine Mucosa IgA IL-10 IL-6 IL-12 Fluid | ↑ up to 50% | ↑ up to 22% | ↑ up to 33% | - [58] |
| Health effect | Model/participants | Bioactive compound | MO | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|--------------------|----|----------------------|-------------------|----------------------------------------------------------|--------------------------|----------------|---------|
| IL-4          | up to 164%         |                    |    |                      |                   |                                                          |                          |                |         |
| IL-12         | up to 67.5%        |                    |    |                      |                   |                                                          |                          |                |         |
| Large intestine |                   |                    |    |                      |                   |                                                          |                          |                |         |
| IgA           | up to 43%          |                    |    |                      |                   |                                                          |                          |                |         |
| IgG           | up to 41.7%        |                    |    |                      |                   |                                                          |                          |                |         |
| IL-4          | up to 44.4%        |                    |    |                      |                   |                                                          |                          |                |         |
| IL-6          | up to 30%          |                    |    |                      |                   |                                                          |                          |                |         |
| IL-10         | up to 47.2%        |                    |    |                      |                   |                                                          |                          |                |         |
| IFN           | up to 21.2%        |                    |    |                      |                   |                                                          |                          |                |         |
| TNF           | up to 20%          |                    |    |                      |                   |                                                          |                          |                |         |
| Serum:        |                    |                    |    |                      |                   |                                                          |                          |                |         |
| IL-4          | up to 209%         |                    |    |                      |                   |                                                          |                          |                |         |
| IL-6          | up to 254%         |                    |    |                      |                   |                                                          |                          |                |         |
| IL-10         | up to 170%         |                    |    |                      |                   |                                                          |                          |                |         |
| IFN           | up to 44%          |                    |    |                      |                   |                                                          |                          |                | [16]    |
| Granuloma weight |                  |                    |    |                      |                   |                                                          |                          |                |         |
| Microorganism growth | Cow’s milk kefir |                    |    |                      |                   |                                                          |                          |                |         |
| BC            | -132.33%           |                    |    |                      |                   |                                                          |                          |                |         |
| KP            | -72.05%            |                    |    |                      |                   |                                                          |                          |                |         |
| SA            | -33.33%            |                    |    |                      |                   |                                                          |                          |                |         |
| SE            | -31.89%            |                    |    |                      |                   |                                                          |                          |                |         |
| LM            | -16.66%            |                    |    |                      |                   |                                                          |                          |                |         |
| PA            | Without effect     |                    |    |                      |                   |                                                          |                          |                |         |
| EC            | Without effect     |                    |    |                      |                   |                                                          |                          |                |         |
| PM            | Without effect     |                    |    |                      |                   |                                                          |                          |                |         |
| Lactic, acetic, and pyruvic acids | Cow milk kefir: mesophilic aerobic bacteria, yeast, Lactobacillus, and Lactococcus | 24 h | Cow milk kefir: 0.90% (w/w) | 1 mL kefir suspension/day | 7 days | | - | [60] |
| Microorganism growth | Donkey milk kefir |                    |    |                      |                   |                                                          |                          |                |         |
| BC            | -183.33%           |                    |    |                      |                   |                                                          |                          |                |         |
| KP            | -17.39%            |                    |    |                      |                   |                                                          |                          |                |         |
| SA            | -4.34%             |                    |    |                      |                   |                                                          |                          |                |         |
| SE            | -16.89%            |                    |    |                      |                   |                                                          |                          |                |         |
| LM            | -58.33%            |                    |    |                      |                   |                                                          |                          |                |         |
| PA            | Without effect     |                    |    |                      |                   |                                                          |                          |                |         |
| EC            | Without effect     |                    |    |                      |                   |                                                          |                          |                |         |
| PM            | -58.33%            |                    |    |                      |                   |                                                          |                          |                |         |
| Acetobacter orientalis, Lactococcus lactis, Lactobacillus gasseri | 25, 50, 75, and 100% (v/v) | 48 h | | | | | Microorganism growth | [14] |
| EC            | -100%              |                    |    |                      |                   |                                                          |                          |                |         |
| Health effect | Model/participants | Bioactive compound | MO\(^1\) Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|-------------------|--------------------|--------------------------------|-----------------|-------------------------------------------------------|----------------------------|----------------|-----------|
|               | Kazachstania unispora, Pichia kudriavzevii, Galactomyces candidum, Geotrichum bryndzae, Lactobacillus kefri, and Saccharomyces cerevisiae | Kefiran | - | 1% (w/v) | 24 h | ST ↓ 100% | [61] |
|               | In vitro: Staphylococcus aureus (SA), Streptococcus faecalis (SF), Pseudomonas aeruginosa (PA), and Escherichia coli (EC) | Kefiran extracted by hot water | | | | EC ↓ 41.6%, PA ↓ 51.3%, SF ↓ 60.2%, AS ↓ 61.6% | | |
|               | In vitro: Pseudomonas aeruginosa (PA) and methicillin-resistant Staphylococcus aureus (MRSA) | FK-1000 (composed of sugars and amino acids) | Lactobacilaceae, Acetobacteraceae, Pseudomonadaceae, Streptococcaceae, Enterobacteriaceae, Alphaproteobacteria, Aeromonadaceae, and Pseudomonadales | 200 µL/well of Muller Hinton | 18 h | MRSA ↓ 100%, PA ↓ 100% | | [62] |
|               | In vitro: Pseudomonas putida extracted from spoiled chicken | Fraction with MM < 6000 in the supernatant | Lactobacillus paracasei FX-6 | 0.078%, 0.156%, 0.3125%, 0.625%, 1.25%, 2.5%, 5.0%, and 10% (w/v) | 21 h | Pseudomonas putida ↓ 13.5% to 98% | Performance on the plasma membrane, DNA and proteins of pathogenic microorganisms | [63] |
|               | In vitro: Escherichia coli (EC), Lactobacillus plantarum (LP), Micrococcus luteus (ML), Listeria monocytogenes (LM), Salmonella enteritidis (SE), Staphylococcus | Bacteriocin | - | 100, 150, 200, and 250 µL/wells with a diameter of 7 mm | 24 h | LP ↑ up to 15 times, ML ↑ up to 20 times | | [40] |

\(^1\) MO: Minimum inhibitory concentration.
| Health effect                                                                 | Model/participants                                                                 | Bioactive compound                                                                 | MO[^1] | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism                                                                 | Reference |
|------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--------|----------------------|-------------------|------------------------------------------------------------|---------------------------|---------------------------------------------------------------------------------|-----------|
| aureus (AS), and Bacillus cereus (BC)                                         |                                                                                     | Bioactive peptides Lactobacillus, Lactococcus, and yeast                           | 2.5% (w/v) | 24 h                |                   | BC up to 2 times; LM up to 4 times                        | up to 8 times            | LC                                                         | [64]      |
|                                                                              |                                                                                     | Lactobacillus kefiransfaciens DN1                                                  | 0.35, 1% and 2.5% (w/v) | 24 h                |                   | SA up to 100%                                             | up to 100%               | -                                                        | [65]      |
|                                                                              |                                                                                     | Exopolysaccharide DN1                                                             | 0.3% (w/v) | 24 h                |                   | LM down 56%                                               | down 56%                 | -                                                        | [66]      |
|                                                                              |                                                                                     | Lactic Acid                                                                        | -       | 25, 50, 75, and 100% (v/v) | 24 h | EC down 33% to 57%                                        | up to 98.7%              | Damage to the outer and inner cell membrane with extravasation of potassium ions and cytoplasmic β-galactosidase binding to the bacterial DNA | [67]      |
|                                                                              |                                                                                     | Biofilms Lactobacillus plantarum                                                  | 10^6 CFU/mL | 12, 24, 36, 48, 60, 72, and 84 h |                   | Microorganism growth MRSA down 1.4% to 30%               | Inhibition of biofilm production by MRSA | -                                                        | [68]      |
|                                                                              |                                                                                     | Lactobacillus paracasei subsp. Tolerans FX-6                                      | 0.00625% (w/v) | 20 h                |                   | Microorganism growth EC down 33% to 57%                  | Damage to the outer and inner cell membrane with extravasation of potassium ions and cytoplasmic β-galactosidase binding to the bacterial DNA | -                                                        | [69]      |
|                                                                              |                                                                                     | Kefiran Lactobacillus kefiransfaciens                                              | 1% (w/v) | 13 h                |                   | Microorganism growth                                      | -                                                        | -                                                        | -         |

[^1]: MO refers to the model organisms.
| Health effect | Model/participants | Bioactive compound | MO | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|-------------------|----|----------------------|-------------------|----------------------------------------------------------|---------------------------|----------------|----------|
| **Continued.** | **Pseudomonas aeruginosa** (PA), **Salmonella Typhimurium** (ST), and **Staphylococcus aureus** (SA) | Lactic and acetic acids | - | 95% (v/v) | 24 h | EC ↓ up to 25.2% PA ↓ up to 19% KP ↓ up to 9.2% ST ↓ up to 3.3% AS ↓ up to 2% | In situ (whey fermented with kefir grains): Aspergillus flavus (AFL), Penicillium crustosum (PC), Aspergillus terreus (AT), Aspergillus Fumigatus (AF), Trichoderma longibrachiatum (TL), Rhizopus sp., and Aspergillus parasiticus (AP) | Microorganism germination | [70] |
| **In situ** | **Thermolabile fraction > 10 kDa in the supernatant** | | | | | | | | |
| **In vitro** | **Supernatant from** Lactococcus lactis subps. lactis or from a mixture of all microorganisms of kefir | | | | | | | | |
| **Effective zone of inhibition** | **Lactic and acetic acids** | | | | | | | | |
| **In vitro** | **Streptococcus faecalis** (SF), **Pseudomonas aeruginosa** (PA), **Salmonella Typhi** (STP), **Bacillus subtilis** (BS), **Bacillus cereus** (BC), **Escherichia coli** (EC), **Klebsiella pneumoniae** (KP), **Staphylococcus aureus** (SA), and **Fusarium graminearum** (FG) | Kefiran | - | 0.1 mL 5 mm diameter paper disks 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, and 10% (v/v) | 24 h for bacteria and yeasts and 7 days for fungi | | Zone of inhibition | | |

---

Oxidative Medicine and Cellular Longevity
| Health effect | Mode/participants | Bioactive compound | MO | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|-------------------|--------------------|----|----------------------|------------------|----------------------------------------------------------|---------------------------|----------------|-----------|
| In vitro: *Salmonella Typhimurium* (ST), *Escherichia coli* (EC), *Pseudomonas aeruginosa* (PA), and *Staphylococcus aureus* (SA) | Lactic acid (partial effect) | - | 0.9% (w/w) | 48 h | Mycelial dry weights ↓ 14.9% to 100% | ↓ Zone of inhibition | - | Industrial kefir | [17] |
| In vitro: *Salmonella enteritidis* (SE) | S-layer proteins | Lactobacillus kefir strains CIDCA 8344 and CIDCA 8348 | 2 × 10⁸ CFU/mL | 4 h | Salmonella enteritidis ↓ up to 99.96% | - | - | [72] |
| In situ (kefir-fermented milk): spores and vegetative cells de *Bacillus cereus* and toxin production by *B. cereus* | Organic acids | - | 1% and 5% (w/v) | 24 h | Vegetative cells ↓ 70% to 99.8% | Number of spores ↓ from 80 to 50,000 times | Reduction of the biological activity of the pathogenic microorganism | [31] |
| In vitro: 2,2-diphenyl-1-picyrylhydrazyl—DPPH; reduce Fe³⁺ to Fe²⁺ (FRAP) | Kefiran | - | 0.08%, 0.04%, 0.02%, 0.01%, and 0.005% (w/v) | 30 min | DPPH ↓ 25 to 85% | FRAP ↓ 37 to 84% | - | [61] |
| In situ (cow milk kefir): 2,2′-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid—ABTS; oxygen radical absorbance capacity—ORAC | Bioactive peptides | - | 20 μL/well (v/v) | 80 min | ORAC ↓ 111.6% | The antioxidant effect cannot be attributed to the ion chelating ability | - | [14] |
| | Kefiran | - | 1% and 0.5% (w/v) | 20 min | - | - | - | - | - |
| Health effect | Model/participants | Bioactive compound | MO$^1$ | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|-------------------|-------|---------------------|------------------|----------------------------------------------------------|---------------------------|-----------------|-----------|
| In vitro: ascorbic acid equivalent reducing capacity (AAEC) | 8.47 μg/mL | Total phenolic compounds | - | 5% (v/v) 8.3% (v/v) 8.3% (v/v) | 3 min 30 min 30 min | Ascorbic acid equivalent reducing capacity | 4.6% to 46% | Metal chelating activity and sequestering activity of hydroxyl and superoxide radical | [73, 74] |
| In situ (cow and ewe milk kefirs) | 2,2'-Azino-bis-3-ethylbenzothiazoline-6-sulfonic acid—ABTS | Bioactive peptides | - | 2.5%, 1.25%, 0.62, and 0.31% (w/v) | 120 min | ABTS | ↑ 2% to 25.6% | - | [64] |
| | 2,2-Diphenyl-1-picrylhydrazyl—DPPH | | | 0.625% (w/v) | 6, 30, 60, 90, 150, and 180 min | DPPH | ↓ 31% to 96% | - | [28] |
| | | | | 2.5% peptides 1.25% peptides 7 days 14 days | Antioxidant activity | ↑ 10% to 20% | Resistance to hydrogen peroxide | [73] |
| | Exopolysaccharides | Bacillus amylobacteriens, Uncultured Bacillus sp. clone, Bacillus subtilis, Bacillus taquilensis, and Bacillus sianensis | 1 mL (10$^8$ CFU/mL)/3 mL | 30 min | AAPH-oxidized BSA protein | ↑ 31% to 96% | - | [28] |
| | Exopolysaccharides | Acetobacter okinawanus, Leucosostoc pseudomesenteroides, and Kazachstania anisopora | 0.05%, 0.1%, 0.15%, 0.20%, and 0.25% (w/v) | 360 min | Antioxidant activity | ↑ 8.43% | - | [74] |
| | Exopolysaccharides | | - | 0.0013% (w/v) | 6 min | Antioxidant activity | ↑ 8.43% | - | [74] |

---

1 MO: Molecular Oxygen

---

In vitro: 2,2-diphenyl-1-picrylhydrazyl—DPPH

In vitro: 2,2-azobis(2-methylnitramide) dihydrochloride—AAPH—in bovine serum albumin (BSA)

In situ (cow milk kefir): 2,2'-Azino-bis-3-ethylbenzothiazoline-6-sulfonic acid—ABTS

---

Oxidative Medicine and Cellular Longevity
Table 2: Continued.

| Health effect | Modell/participants | Bioactive compound | MO$^1$ | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|---------------------|--------------------|--------|----------------------|-------------------|--------------------------------------------------------|----------------------------|-----------------|-----------|
| In situ (goat milk kefir): 2,2', -azino-bis-3-ethylbenzothiazoline-6-sulfonic acid—ABTS, oxygen radical absorbance capacity—ORAC | Phenolic compounds | - | 38.93, 61.60, 26.62, and 123.23% (w/v) | - | ABTS | 62% to 120% | | | [75] |
| Lipid accumulation in adipocytes | | | | | | | | | | |
| 0.01 mg/dL LMDH4 | | | | | | | | | | |
| Other strains | | | | | | | | | | |
| 0.1 mg/dL LMDH4 | | | | | | | | | | |
| LMDH7 | | | | | | | | | | |
| LMDH5 | | | | | | | | | | |
| Other strains | | | | | | | | | | |
| 0.2 mg/dL LMDH7 | | | | | | | | | | |
| LDMH4 | | | | | | | | | | |
| LKDH3 | | | | | | | | | | |
| LKDH5 | | | | | | | | | | |
| LMDH6 | | | | | | | | | | |
| Other strains | | | | | | | | | | |
| In vivo: C57BL/6J high-fat and high-fructose diet-induced obese mice and with oral administration of heat-killed lactic acid bacteria (HLAB) from kefir | | | | | | | | | | |
| In vitro: Lactococcus lactis WH-C1 from kefir in GM17 broth supplemented with cholesterol (30 mg/100 mL) | | | | | | | | | | |
| Exopolysaccharides | Lactobacillus kefir (LKDHI, LKDHS, and LKDHS strains) and Leuconostoc mesenteroides (LMDH4, LMDH6, LMDH7, LMDH8, and LMDH9 strains) | 0.01 mg/mL, 0.1 mg/mL, and 0.2 mg/mL of | - | | | | | | | |
| | | | | | | | | | | |
| Lactobacillus kefir | LMDH4 and Lactobacillus kefir LKDH5 | | | | | | | | | |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Exopolysaccharides | Leuconostoc mesenteroides LMDH4 and Lactobacillus kefir LKDH5 | 10 mL/kg bw of a mixture Leuconostoc mesenteroides LMDH4 (3 × 10$^{10}$ CFU/mL) and Lactobacillus kefir LKDH5 (1 × 10$^{9}$ CFU/mL) | 8 weeks | | | | | | | [76] |
| | | | | | | | | | | |
| | | | | | | | | | | |
| Exopolysaccharides | Lactococcus lactis WH-C1 | 4% (v/v) inoculum Lactococcus lactis WH-C1 from Tibet kefir grains | 24 h | Cholesterol in the medium | | | | | | [77] |
| Health effect | Model/participants | Bioactive compound | MO<sup>1</sup> | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|-------------------|-------------------|---------------|---------------------|----------------|----------------------------------------------------------|--------------------------|----------------|-----------|
| Blood pressure | *In situ* (cow milk kefir): assay of inhibitory activity on angiotensin-converting enzyme (ACE) | Bioactive peptides | - | 11.2 mg/100 mL | 24 h | ACE activity ↓98.4% | - | - | [14] |
| Glucose | *In vivo*: C57BL/6J high-fat and high-fructose diet-induced obese mice and with oral administration of heat-killed lactic acid bacteria (HLAB) from kefir | Exopolysaccharides *Lactobacillus kefir* LKD15 | LMDH4 and *Lactobacillus kefir* LKD15 | 10 mL/kg bw of a mixture LMDH4 (1 × 10<sup>10</sup> CFU/mL) and *Lactobacillus kefir* LKD15 (1 × 10<sup>9</sup> CFU/mL) | 8 weeks | Plasma glucose Without effect | - | - | [76] |
| Glucose | *In vivo*: Streptozotocin-nicotinamide-(STZ-NA-) induced diabetic rats/male rats of 8-12 weeks old | Alcohol and phenolic compounds | - | 5 to 20 mL kefir with black rice extract (1:1)/kg bw | 4 weeks | Number of Langerhans islet insulin-positive β-cells | ↑ up to 199% | L. paracasei CIDCA 8339 | [78] |
| | | | | | | | | Lentivirusae | 32% |
| | | | | | | | Firmicutes | 12% |
| | | | | | | | Verrucomicrobi | 33% |
| | | | | | | | Acidaminococcaceae | 15% |
| | | | | | | | Comamonas | 16% |
| | | | | | | | Proteobacteria | 31% |
| | | | | | | | Bacteroidetes | 11% |
| | | | | | | | Actinobacteria | 1.5% |
| | | | | | | | L. paracasei CIDCA 83124 | ↑ up to 2330% | Proton-radical scavenging activity | - | [79] |
| Intestinal microbiota modulation | *In vivo*: fecal samples from healthy children aged between 8 months and 3 years old | Exopolysaccharides 8339 and 83124 | *L. paracasei* CIDCA 8339 and CIDCA 83124 | 0.3% (w/v) | 72 h | Firmicutes/Bacteroidetes ↑17% | ↓ 31% | L. paracasei CIDCA 83124 | [80] |
| | | | | | | | Proteobacteria | 15% |
| | | | | | | | Comamonas | 52% |
| | | | | | | | Firmicutes | 17% |
| | | | | | | | Bacteroidetes | 10% |
| | | | | | | | Actinobacteria | 1.3% |
| | | | | | | | Escherichia | 2.8% |
| | | | | | | | Bacteroides | ↓11% to 12% |
| | | | | | | | Klebsiella | 16% |
| | | | | | | | Firmicutes | 17% |
| | | | | | | | Bacteroidetes | 10% |
| | | | | | | | Alloprevotella | 326% |
| | | | | | | | Romboustia | 85% |
| | | | | | | | Anaerostipes | 66% |
| Health effect                                                                 | Model/participants                                       | Bioactive compound | MO\(^1\) | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism                                                                 | Reference |
|-----------------------------------------------------------------------------|----------------------------------------------------------|--------------------|----------|----------------------|-------------------|-----------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------|-----------|
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus                                             | ↓55%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Parasutterella                                            | ↓46%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Streptococcus                                             | ↓39%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Firmicutes/Bacteroidetes                                  | ↑0.04% to 1.8%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillace                                            | ↑14.59%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus (day 7)                                      | ↑15.12%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Bifidobacteriace                                          | ↑0.2% to 0.59%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Rikenellace                                               | ↑2.63% to 2.74%           | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Abundance in the gender                                   | ↓up to 39.19%             | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | In vivo: male Balb\(^c\) mice aged 16 weeks              |                          | -                                                                               | [82]      |
|                                                                            |                                                            |                    |          |                      |                   | Exopolysaccharide                                         |                          | -                                                                               | [82]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillus kefiranfaciens XL10                        | 0.4 mL of an XL10 suspension (10\(^8\) CFU/mL) | 21 days                  | Ruminococcus, Parasutterella, Streptococcus, Firmicutes/Bacteroidetes, Lactobacillace, Ruminococcus (day 7) | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus                                             | ↓55%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Parasutterella                                            | ↓46%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Streptococcus                                             | ↓39%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Firmicutes/Bacteroidetes                                  | ↑0.04% to 1.8%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillace                                            | ↑14.59%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus (day 7)                                      | ↑15.12%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Bifidobacteriace                                          | ↑0.2% to 0.59%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Rikenellace                                               | ↑2.63% to 2.74%           | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Abundance in the gender                                   | ↓up to 39.19%             | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | BALB/c female mice (6 to 8 weeks old)                    |                          | -                                                                               | [82]      |
|                                                                            |                                                            |                    |          |                      |                   | Kefiran                                                   | Daily intake 0.75 to 1 mg kefiran per day | 21 days                  | Bifidobacteria                                                                  | [82]      |
|                                                                            |                                                            |                    |          |                      |                   | Exopolysaccharide                                         |                          | -                                                                               | [82]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillus kefiranfaciens XL10                        | 0.4 mL of an XL10 suspension (10\(^8\) CFU/mL) | 21 days                  | Ruminococcus, Parasutterella, Streptococcus, Firmicutes/Bacteroidetes, Lactobacillace, Ruminococcus (day 7) | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus                                             | ↓55%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Parasutterella                                            | ↓46%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Streptococcus                                             | ↓39%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Firmicutes/Bacteroidetes                                  | ↑0.04% to 1.8%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillace                                            | ↑14.59%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus (day 7)                                      | ↑15.12%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Bifidobacteriace                                          | ↑0.2% to 0.59%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Rikenellace                                               | ↑2.63% to 2.74%           | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Abundance in the gender                                   | ↓up to 39.19%             | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | In vitro: Bifidobacterium bifidum PRL2010                |                          | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Kefiran                                                   | 0.3% (w/v)                 | 72 h                  | Bifidobacterium PRL2010                                                        | [41]      |
|                                                                            |                                                            |                    |          |                      |                   | Exopolysaccharide                                         |                          | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillus plantarum YW11                              | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | 12 weeks                  | Ruminococcus, Parasutterella, Streptococcus, Firmicutes/Bacteroidetes, Lactobacillace, Ruminococcus (day 7) | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus                                             | ↓55%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Parasutterella                                            | ↓46%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Streptococcus                                             | ↓39%                      | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Firmicutes/Bacteroidetes                                  | ↑0.04% to 1.8%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillace                                            | ↑14.59%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus (day 7)                                      | ↑15.12%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Bifidobacteriace                                          | ↑0.2% to 0.59%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Rikenellace                                               | ↑2.63% to 2.74%           | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Abundance in the gender                                   | ↓up to 39.19%             | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | In vivo: MTT assay of PC12 cell line (from rat adrenal gland -phaeochromocytoma) |                          | -                                                                               | [46]      |
|                                                                            |                                                            |                    |          |                      |                   | Kefiran                                                   | 5 and 10%                  | 1 to 6 days | Cell viability                                                                  | [46]      |
|                                                                            |                                                            |                    |          |                      |                   | Exopolysaccharide                                         | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution | Low dose: 20 mL/kg bw/day of 1 mg/ml EPS solution |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus                                             | ↓27.7%                    | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Parasutterella                                            | ↓38.18%                   | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Streptococcus                                             | ↓49.6%                    | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Firmicutes/Bacteroidetes                                  | ↓21.5%                    | -                                                                               | [83]      |
|                                                                            |                                                            |                    |          |                      |                   | Lactobacillace                                            | ↑14.59%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Ruminococcus (day 7)                                      | ↑15.12%                   | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Bifidobacteriace                                          | ↑0.2% to 0.59%            | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Rikenellace                                               | ↑2.63% to 2.74%           | -                                                                               | [81]      |
|                                                                            |                                                            |                    |          |                      |                   | Abundance in the gender                                   | ↓up to 39.19%             | -                                                                               | [81]      |

1. MO: Reference concentration.
| Health effect | Model/participants | Bioactive compound | MO1 | Concentration tested | Intervention time | Effect tested/condition/bioactive compound concentration | Effect compared to control | Action mechanism | Reference |
|---------------|--------------------|--------------------|-----|----------------------|-------------------|----------------------------------------------------------|---------------------------|-----------------|-----------|
| Osteoporosis  | In vivo: thirty 16-week-old female C57BL/6J ovariectomized mice | Bioactive peptides (KPS) | -   | 100 mg of KPs/kg bw  | 56 days           | SOD ↑ 33.14%                                             | CAT ↑ 61.09%              | -               | [80]      |

1 Producer microorganism. ↑: increase; ↓: decrease; EPS: exopolysaccharide; IL: interleukin; TNF-α: tumor necrosis factor-α; IFN: interferon; ZO-1: zonula occludens-1; NO: nitric oxide; PBMC: peripheral blood mononuclear cell; DSS: dextran sulfate sodium; TNBS: 2,4,6-trinitrobenzene sulfonic acid; FliC: flagellin; DO: optical density; CCL20: chemokine-ligand-20; bw: body weight; MPO: myeloperoxidase; MDA: malondialdehyde; GSH-Px: glutathione peroxidase; SOD: superoxide dismutase; CAT: catalase; T-AOC: total antioxidant capacity; MTT: (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl); Cyto-c: cytochrome c; BAX: BCL2-associated X; BAD: BCL2-associated agonist of cell death.
The ultrasound combined with hot water in the kefir extraction process showed synergistic results about the antimicrobial activity compared to the kefiran extracted by the isolated methods [61]. *Lactobacillus kefiranofaciens* DN1 produced an EPS—composed of mannose, arabinose, glucose, galactose, and rhamnose—which at 0.3% demonstrated a bacteriostatic effect against *Listeria monocytogenes* and *Salmonella enteritidis*. In higher concentrations (1% and 2.5%), the bactericidal effect was obtained by completely inhibiting the growth of both microorganisms, being considered a new bioactive compound that can be used as a natural antimicrobial [65].

Organic acids are other antimicrobial compounds produced by kefir microorganisms. In this context, lactic acid was a bioactive compound associated with the antimicrobial effect of cow milk kefir and donkey milk kefir. Donkey milk kefir reduced *Klebsiella pneumoniae*, *Bacillus cereus*, and *Proteus mirabilis* by 8%, 37%, and 58% compared to the kanamycin antibiotic. In contrast, cow milk kefir decreased *B. cereus* by 12.9% while had the same impact on *Proteus mirabilis* compared to kanamycin, demonstrating the tremendous antimicrobial potential associated with lactic acid [60, 66]. However, there was no antimicrobial effect against *Pseudomonas aeruginosa* [17, 60]. Other organic acids present in kefir, such as acetic and pyruvic acid, also demonstrated an antimicrobial effect when administered together with lactic acid [14, 31, 70]. Kakisu et al. [31] identified that organic acids act against the germination of *B. cereus* spores in a dose-dependent manner. Using a higher concentration of kefir grains (5%) for the fermentation of milk reduced the pH value more significantly and more quickly, inhibiting the germination of the spores. This more significant lowering of the pH may be associated with more outstanding organic acid production in the medium and, consequently, a more significant antimicrobial effect. Moreover, kefir grains at 5% reduced in a range of 33.3% to 61.8% the output of NheA toxin by *B. cereus* [31].

Bacteriocin, a bioactive protein produced by microorganisms in kefir, demonstrated antimicrobial effects against several microorganisms. In this context, *Lactobacillus plantarum*, *Micrococcus luteus*, *Listeria monocytogenes*, *Salmonella enterica* serovar *Enteritidis*, *Staphylococcus aureus*, and *Bacillus cereus* were sensible when compared to the negative control (sterile deionized water). In contrast, *E. coli* proved resistant to the antimicrobial action of the bacteriocin. However, it is essential to note that *E. coli* was also resistant to the positive controls, nisin, and polysyne, which are natural antimicrobial peptides commonly employed as preservatives by the food industry. For *S. enterica*, antimicrobial effects similar to nisin were observed [40].

Some microorganisms in kefir produced fractions with antimicrobial activity against *Clostridium difficile*, *Pseudomonas putida*, *Pseudomonas aeruginosa*, and methicillin-resistant *Staphylococcus aureus* [59, 62, 63]. FK-1000 at 25 mg/mL inhibited the growth of *Pseudomonas aeruginosa* by 91%. However, even when in a lower concentration (0.25 mg/mL), FK-1000 presented a synergistic effect with streptomycin, potentiating five times the outcome of this antibiotic. It demonstrates the potential of FK-1000 for use in combination therapy. Another important aspect is that a 50 mg/mL concentration of FK-1000 was not toxic to human epithelial cells, increasing the relevance of this compound’s use as a treatment [62].

In addition, thermolabile fraction greater than 10 kDa produced by *Lactococcus lactis* subsp. *lactis* CIDCA 8221 showed to inhibit the toxigenic effect of *C. difficile*; the fraction inhibited the interruption of the actin network and displacement of Vero cells caused by *C. difficile*. Also, a reduction in the formation of TcdA and TcdB toxins by *Clostridium* has been observed [59].

The proteolysis in the milk by kefir’s microorganisms during fermentation leads to bioactive peptides with antimicrobial activity. F1 bioactive peptides reduced *E. coli* growth in a range of 33% to 57%. Consistently, a mixture of bioactive peptides from kefir had antimicrobial activity against several microorganisms such as *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, *Bacillus cereus*, *Bacillus subtilis*, and *Staphylococcus aureus* [64, 68].

However, it is essential to note that the bioactive compounds from kefir appear to have different antimicrobial potencies. In general, when comparing interventions with similar target microorganisms (E. coli, *S. typhimurium*, and *S. aureus*), the concentration and time of intervention with organic acids were substantially higher (40 and 2 times, respectively) than for interventions with kefiran or bioactive peptides (Table 2). Therefore, kefiran and bioactive peptides may have more potent effects than organic acids, requiring lower concentrations for similar antimicrobial results. However, this premise needs further investigation.

*Lactobacillus plantarum*, a microorganism present in kefir grains, produces a biofilm that acts as an antimicrobial, inhibiting the growth of methicillin-resistant *Staphylococcus aureus* in the range of 1.4 to 30%. Medium’s time, temperature, and aeration influenced the biofilm production by the kefir’s microorganism, which may be related to cell maturations, enzymatic reactions, and activation expression of specific genes. Thus, external factors and factors related to the strain used can influence the antimicrobial activity associated with the production of biofilms by *Lactobacillus plantarum* [67].

Finally, the inhibitory effect of some microorganisms present in the kefir about pathogens may be associated with the presence of S-layer proteins on the outer surface of their cell membrane. Thus, the preincubation of *Lactobacillus kefir* with *S. enteritidis* allowed direct interaction between them through the S-layer proteins of *L. kefir*, reducing then the sites binding to enterocytes on the pathogen’s cell membrane. In addition, S-layer proteins from *Lactobacillus kefir* strains also decreased the viability of *Salmonella enteritidis*. Interestingly, even S-layer proteins obtained from noncoaggregation strains, which do not interact with *Salmonella*, could interact with *S. enteritidis*. The conformation and the active groups present in the S-layer may differ between the protein isolated in the solution and the one present on the bacterium’s surface (*Lactobacillus kefir*). Therefore, S-layer proteins have the potential to be used as a natural antimicrobial [72].

The meta-analysis for the antimicrobial category corroborates with the systematic review findings herein, as results
show a statistically significant overall effect of kefir bioactive compounds against bacteria and fungi (Supplementary Figure S1). As the distinct outcomes’ measurements differed between trials, we used the standardized mean differences (SMDs) to estimate the effects, whereas a negative SMD value indicates microbial reduction. Therefore, the standard mean differences (SMDs) were estimated for the overall antimicrobial effect (SMD (-1.35) (95% CI: -1.79–0.91, P ≤ .001)) and separately for fungi (SMD (-7.18) (95% CI: -9.08–5.28, P ≤ .001)), *Bacillus cereus* (SMD (-0.25) (95% CI: -1.06–0.56, P = 0.54)), *Escherichia coli* (SMD (-0.67) (95% CI: -2.26–0.92, P = 0.41)), *Klebsiella pneumoniae* (SMD (-1.79), (95% CI: -4.22–0.63, P = 0.15)), *Pseudomonas* spp. (SMD (-1.98), (95% CI: -3.48–0.49, P = 0.009)), *Salmonella* spp. (SMD (-0.53), (95% CI: -3.14–0.06, P = 0.08)), and *Staphylococcus* spp. (SMD (-0.88), (95% CI: -1.81–0.06, P = 0.07)) as showed in the Supplementary Figure S1. In this context, kefir demonstrated a statistical significance concerning the overall antimicrobial effect, although the bioactive compounds from kefir only had significant effects against fungi and *Pseudomonas* spp. However, we can see a tendency to favor kefir treatments for all the studied microorganisms, although not statistically significant.

To assess the heterogeneity of the data, I² tests for all nine analyses showed statistically significant considerable heterogeneity for fungi (I² = 83%, P ≤ .001) and statistically significant moderate heterogeneity for overall antimicrobial effect (I² = 72%, P ≤ .001), *Bacillus cereus* (I² = 63%, P ≤ .001), *Escherichia coli* (I² = 67%, P ≤ .001), *Klebsiella pneumoniae* (I² = 64%, P = 0.004), *Pseudomonas* spp. (I² = 61%, P = 0.0003), and *Salmonella* spp. (I² = 68%, P ≤ .00001).

Despite the scarcity of studies investigating antimicrobials’ mechanisms, these mechanisms appear diverse, presenting singularity for each type of bioactive compound. For bioactive peptides, the action occurs on the cell membrane and the pathogen’s DNA, while organic acids reduce biological activity. Biofilms, in turn, inhibit the production of biofilm by the pathogenic microorganism (Figure 2). In this context, bioactive compounds form pores in the pathogen’s membrane, which damages the integrity of the plasma membrane, increasing its permeability with consequent efflux of potassium ions, leakage of proteins, and nucleic acids. These compounds also were described bind to the genomic DNA of the pathogen [64, 68].

It is essential to highlight that although the *in vitro* and *in situ* studies imply an antimicrobial role of bioactive compounds from kefir, the absence of controlled *in vivo* studies is a gap in the literature that limits the assessment of the extent of this effect in physiological systems.

3.4.2. Antioxidant Activity. The intervention with antioxidant molecules is crucial since they interact with free...
The main bioactive compounds identified with antioxidant activity from kefir were the EPS, including kefiran, although bioactive peptides and phenolic compounds were also described (Table 2). In addition, there have been few studies identifying the producing microorganisms of the compounds with antioxidant properties. However, the *Acetobacter*, *Leuconostoc*, *Bacillus*, and *Kazachstan* genera strains were reported (Table 2). Concerning the precursors in milk, there was an evident scarcity of their investigation; only one study identified the precursors of bioactive peptides as being β-casein, k-casein, αs1-casein, and αs2-casein [64].

The antioxidant activity of kefiran in vitro was 8.47 μg/mL and 4.44 μg/mL, for 1% and 0.5% concentrations, respectively, as measured by reducing power activity in ascorbic acid equivalent capacity (AAEC). Interestingly, the hyaluronic acid used in gold standard viscosupplementation treatment did not demonstrate reducing power at similar concentrations to those employed for kefir. It shows the antioxidant potential of the compound isolated from kefir [54]. The scavenging of free radicals and ferric ion reduction represented 25% to 85% and 37% to 84%, respectively, of vitamin C activity, which is considered a positive control for these activities. The relatively low concentrations (0.005% to 0.08%) tested of kefir can justify its inferior effect compared to vitamin C [61].

The antioxidant activity of the EPS produced by microorganisms in the kefir promoted the protection of biological molecules from oxidation. Inline, low concentrations of EPS (0.05% to 0.25%) could protect BSA protein from oxidation induced by APPH (2,2-azobis[2-methylpropionamide] dihydrochloride). The protein oxidation-decrease ranged from 31% to 96%. Interestingly, this protection was higher than observed in the negative control (protein without induced oxidation) [28]. In addition, the antioxidant capacity in situ related to EPS was higher 8.43% after 24 hours of fermentation [74]. The ability to eliminate the DPPH (1,1-diphenyl-2-picrilhidrazil) free radical, turn in, increased from 10% to 20%. This fact can be attributed to the metabolic activity of kefir microorganisms during fermentation, leading to the production and accumulation of EPS. Thus, studies have found that the EPS present in kefir demonstrates potential as an antioxidant agent [73]. The EPS also confers resistance to hydrogen peroxide, completely reversing the detrimental effect of this compound on the cell growth of microorganisms present in the kefir. Consistent, cells without EPS significantly lose resistance to hydrogen peroxide [73].

Smaller fractions present in kefir, such as bioactive peptides, also demonstrated an antioxidant effect. An enhancement in scavenging ability of oxidized 2,2′-zino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) ranged from 2% to 25.6% for sheep’s milk kefir and 35.8% for cow’s milk kefir both compared to control [14, 64]. A significant improvement (111.6%) in oxygen radical absorbance capacity (ORAC) for cow’s milk kefir confirmed the antioxidant activity of bioactive peptides [14]. We believe that the observed difference between the antioxidant activity of sheep’s milk kefir and cow’s milk kefir may be associated with the difference in composition between milk, especially about the protein content and its design which are precursors of bioactive peptides. This finding highlights the relevance of identifying the precursors of bioactive compounds in milk to increase its functional potential.

The fermentative process of milk by kefir grains showed to elevate its antioxidant activity by synthesizing phenolic compounds. In artisanal kefir, the antioxidant capacity was increased up to 120% when measured by ABTS and up to 40% by ORAC [75]. In contrast, for commercial kefir, the antioxidant capacity by ABTS reduced, while that by FRAP—ferric antioxidant power—increased [85]. Thus, phenolic compounds produced by starter culture appear to exert antioxidant action through their reducing power but are ineffective as to the scavenging ability of oxidized compounds. Still, the DPPH scavenging varied according to the type of kefir, reducing in ewe kefir and increasing in cow kefir compared to control [85]. Therefore, according to the matrix, the profile of phenolic compounds can influence the in situ radical scavenging ability. Indeed, Satir and Guzel-Seydim [75] observed increased antioxidant activity in the presence of gallic acid, catechin, epicatechin, caffeic acid, p-coumaric acid, chlorogenic acid, ferulic acid, and photocatechuic acid. Phenolic compounds resulting from the metabolic activity of kefir microorganisms can improve up to 120% of the in situ antioxidant capacity during fermentation [85].

The intervention times were more remarkable for bioactive peptides than EPS and phenolic compounds for similar methodologies (Table 2). This finding suggests that the peptides need a longer time to exert significant antioxidant activity. On the other hand, phenolic compounds required concentrations up to 3 times higher than other bioactive compounds (Table 2).

Consistent with the described findings, the meta-analysis showed an antioxidant tendency of the kefir bioactive compounds. However, it was not considered statistically significant compared to control treatments, even though we observed a narrow confidence interval. It resulted in a standard mean difference (SMD) of (SMD -0.83) (95% CI: -1.65–0.00, P = 0.05) (Supplementary Figure S2). Besides, the outcomes of the studies showed a significant substantial heterogeneity (I² = 84%, P ≤ .001), which may have contributed to the lack of significance.

Although there is a scarcity of description of the mechanisms of action in the literature, EPS seems to exercise effect through metal chelating activity and sequestering activity of hydroxyl and superoxide radicals, with consequent resistance to the hydrogen peroxide. In contrast, the antioxidant activity of bioactive peptides cannot be attributed to the ion chelating ability [14].

As reported previously for antimicrobial effect, the absence of controlled *in vivo* experiments evaluating the antioxidant potential of bioactive compounds from kefir is a gap in the literature that limits assessing the extent of this effect in physiological systems.
3.4.3. Modulation of the Intestinal Microbiota. Maintaining the intestinal microbiota in symbiosis with the host is essential for human health since it favors the integrity of the intestinal barrier, the balance of the immune system, and controlling inflammatory processes. Therefore, the search for probiotics or bioactive compounds which favor the modulation of the intestinal microbiota has been extensively studied in the recent literature.

Exopolysaccharides (EPSs), including kefiran, were the predominant described bioactive compounds capable of modulating the intestinal microbiota in vitro and in vivo models (Table 2). However, there is a lack of studies identifying the precursors of these bioactive compounds. In addition, the scarcity of studies determining the microorganisms that produce them in milk highlights a gap in the literature. Interestingly, the concentration and intervention time using bioactive peptides was considerably higher than those with EPS for in vivo animal models; the concentration employed of peptides was up to 2.5-fold greater. The intervention time was up to 2.6-fold longer compared to EPS use (Table 2). It suggests that EPS can be a bioactive compound more potent for gut modulation. However, this premise needs further investigation.

EPS produced by L. paracasei CIDCA 8339 and CIDCA 83124 in kefir demonstrated modifying the microbiota present in infant fecal samples and, consequently, changing the short-chain fatty acid profile (SCFA). The butyric and propionic acids produced are compounds with biological activity associated with health benefits. Among these benefits stand out as follows: strengthening the intestinal epithelial barrier and inhibiting the cholesterol synthesis at the liver. Still, the expression of leptin, YY polypeptide (PPY), and glucagon-like peptide 1 (GLP-1) promoted by them regulate the lipogenesis in adipose tissue and the appetite [79].

Considering the phylum level, the use of EPS and bioactive peptides commonly improved Firmicutes to the detriment of Bacteroidetes, as demonstrated in Table 2. Regarding the genus level, a reduction in microorganisms associated with pathogenicities, such as Klebsiella and Escherichia, has been reported, demonstrating the potential of EPS in contributing to a healthy intestinal microbiota [79]. The concomitant decrease in Rikenellaceae is also a promoter of the health of colon epithelial tissue [81]. In contrast, EPS favored Viciialis, Acidaminococcus, Comamonas, and the Ruminococcaceae family [79, 81]. Selecting certain species of the Acidaminococcus genus may be responsible for increasing organic acids such as propionate and butyrate, which are beneficial in intestinal levels.

On the other hand, the modulation of other genera also considered beneficial to health, such as Lactobacillus and Bifidobacterium, depended on the bioactive compound used during the intervention (Table 2). Thus, Lactobacillus and Bifidobacterium were not favored by EPSs 8339 and 83124 in Bengoa et al. [79]. In contrast, in the study of Xing et al. [81], using adult male mice, EPS produced by Lactobacillus kefiranofaciens XL10 provided growth of 14.59% for Lactobacillaceae and up to 0.59% for Bifidobacteriaceae. Growth of up to 17% in Bifidobacterium in adult female mice was also observed when using kefiran, although no change was observed in the Lactobacillus population [82]. In vitro, 0.3% kefiran elevated a Bifidobacterium bifidum PRL2010 population up to 5.8 × 10^6 CFU/mL. In contrast, there was not Bifidobacteria population growth in the control (medium without carbon source). This fact indicates that the target microorganisms should be considered in deciding the most appropriate bioactive compound for intestinal modulation in each intervention.

Interestingly, EPS was more potent in promoting intestinal microbiota diversity than inulin, a prebiotic commonly used by the food industry. Still, EPS led to a different short-chain fatty acid profile, increasing the butyrate content and benefiting the gut microbial population more than inulin [79]. Kefiran also proved to be a better source of carbon than glucose for the growth of Bifidobacterium bifidum PRL2010; kefiran increased the development of the strain by 20 to 700% compared to the use of glucose [41].

Bioactive peptides, other bioactive compounds present in kefir, were also related to changes in the intestinal microbiota. The oral administration of peptides to female mice partially reversed the detrimental effect on the intestinal microbiota caused by oophorectomy; the peptides from kefir reduced 46% of Parasutterella and 39% of Streptococcus. Bacteria potentially pathogenic belonging to genera Klebsiella and Escherichia were also decreased. Romboutsia, together with Streptococcus, has been linked to obesity and presented an 86% reduction (Table 2). Bioactive peptides from kefir elevated the Alloprevotella population by more than 30% by reducing oophorectomy-induced renal fat accumulation. Ruminococcus-1, SCFA producer bacteria, increased in ovariectomized mice, subsequently decreasing with bioactive peptides' administration. It is essential to highlight that the growth of butyrate-producing bacteria after estrogen deficiency in ovariectomized mice can negatively lead to a detrimental accumulation of SCFAs in the intestine. In contrast, bioactive peptides have not been able to restore the reduction in the Deferrribacteres phylum caused by oophorectomy; the decrease of Deferrribacteres is related to the detriment of vitamins and amino acid metabolism [80].

Thus, bioactive peptides can enrich beneficial bacteria and decreasing potentially harmful pathogens in the gut of ovariectomized females [80]. Still, these findings reveal that further studies, analyzing the relationship between intestinal microbiota and estrogen deficiency and the role of the bioactive peptides from kefir in this relationship, are necessary for a better understanding.

Concerning the richness and diversity of microbiota, interestingly, it is not affected by bioactive peptides in ovariectomized mice. However, peptides significantly improve intestinal microbiota diversity compared to control without ovariectomized procedure [80].

Regarding meta-analysis, treatments with bioactive compounds did not present statistically significant effects on gut microbiota modulation compared to control treatments (SMD (-0.39) (95% CI: -1.32–0.54, P = 0.41) (Supplementary Figure S3). However, we can notice a tendency that favors bioactive efficacy, consistent with our findings. This analysis presented a statistically significant moderate heterogeneity (I^2 = 58%, P < .001), which may have contributed at least partially to the lack of significance.
Finally, most studies failed to evaluate the mechanisms of action of the bioactive compounds on gut microbiota modulation, representing a gap in the literature. However, enhanced transcription of genes involved in the microbe-host interaction was proposed for the kefir action.

3.4.4. Immune Response Modulation. Bioactive compounds from kefir exerted an anti- or proinflammatory impact depending on the model’s presence or absence of inflammatory insult. Thus, they exerted an inhibitory effect in inflammatory diseases’ models, while they had an immunostimulatory effect for models without inflammatory insult (Table 2).

The predominantly studied inflammatory disease model was that of acute colitis, both in vitro and in vivo. For colitis, mainly EPS and extracellular vesicles, but also lactate, they have been described to have an anti-inflammatory role against a variety of acute inflammatory insults: DSS (dextran sulfate sodium), TNFα, FliC (flagellin), IL-1β, and TNBS (2,4,6-trinitrobenzene sulfonic acid). For chronic colitis, extracellular vesicles presented an anti-inflammatory effect against piroxicam. Kefiran, in turn, had an inhibitory effect on cotton-induced granuloma in rats (Table 2). The L. kefiranum, L. kefir, L. kefranofaciens, and L. paracasei species were responsible for producing these bioactive compounds. Therefore, the Lactobacillus genus seems relevant for making anti-inflammatory compounds in the kefir [13, 50, 53]. Galactose and glucose, and to a lesser extent, mannose, arabinose, and rhamnose, were the significant precursors of the polysaccharide component of the bioactive compounds [55].

Extracellular vesicles at 100 μg/mL from L. kefiranum reduced the gene expression of IL-2, IL-8, and TNFα proinflammatory cytokines by 58, 64, and 67%, respectively, in Caco-2 cells for DSS-induced acute colitis model [50]. Extracellular vesicles (1 x 10⁸ particles/mL) also inhibited TNFα-induced colitis. They reduced the expression and secretion of IL-8 by 65 and 96%, respectively, in the Caco-2 cell line. Interestingly, the extracellular vesicles were just as effective as budesonide [53], a glucocorticoid steroid commonly used to treat Crohn’s disease (inflammatory bowel disease) [86]. Still, treatment of Caco-2 cells with extracellular vesicles showed a longer intervention time than treatments with EPS or lactate. In addition, the effect observed with preincubation of cells with EPS or lactate (Table 2) indicates the potential of these compounds as preventive agents of intestinal inflammation. However, further studies exploring pre- and postincubation concerning the inflammatory insult must be conducted to elucidate these bioactive agents’ preventive and therapeutic potentials.

In mice, oral administration of extracellular vesicles could mitigate acute and chronic colitis, corroborating the previous findings in vitro. For DSS-induced acute colitis, both high and low dosages of vesicles prevented weight loss in mice by up to 16% and reduced damage to colon tissue by up to 63%. However, only the highest dosage (3 mg/kg bw) reduced colon atrophy by 29.6%. Similarly, only the highest dosage mitigated colon atrophy by 14.3% for chronic colitis aggravated by piroxicam. Nevertheless, both dosages reduced colon histological damage by up to 85%.

In contrast to acute colitis, ingestion of extracellular vesicles was ineffective in preventing weight loss in chronic colitis [50]. Therefore, due to the broader effects obtained for 3 mg/kg bw, the high dosage seemed more effective for chronic and acute colitis treatment. Vesicles’ administration against TNBS-induced acute colitis also effectively prevented the mouse weight loss by up to 12.5% at 3 x 10⁸ and 3 x 10¹⁰ vesicles/head. Moreover, the administration reduced rectal bleeding and diarrheal condition severity by 75 and 91%, respectively. Damage to colon tissue, in turn, was decreased by up to 85% [53]. Therapy with vesicles from Lactobacillus of kefir was more effective than the prednisolone drug (2 mg/kg) in preventing weight loss, the severity of rectal bleeding, and diarrheal conditions as well as in mitigating colon histological damage [53]. Prednisolone is an anti-inflammatory steroid used to treat inflammation in colitis and Crohn’s disease; however, it does not prevent recurrence of the disease, in addition to having several side effects [87, 88]. Therefore, treatment with bioactive compounds from kefir would be promising both for effectiveness and reduced side effects.

Suspensions of EPS-producer Lactobacillus paracasei (OP390 = 0.25) inhibited by up to 55% the induction of the CCL20 proinflammatory promoter in Caco-2 cells for flagellin-induced acute colitis model. Lactobacillus paracasei CIDCA 8339 strain showed more dramatic anti-inflammatory potential than the other tested strains [13], which indicates that the functional potential of the EPS is strain-dependent. Similarly, lactate at 100 mM inhibited by 78, 80, and 42% the CCL20 promoter induction by flagellin, IL-1β, and TNFα, respectively, in Caco-2 cells. Inline, human intestinal epithelial cells express the lactate receptor. Still, lactate solution and supernatant from kefir with corresponding lactate concentration showed similar inhibitory effects on Caco-2 cells [56], indicating that the kefir matrix does not reduce the impact of this bioactive compound. In vivo, oral administration of kefran-rich kefir supernatant (1 mL/day) was responsible for reducing the weight of cotton-induced abdominal granulomas by 44% in rats. Kefir was as effective as dexamethasone (0.2 mg/kg) in reducing these granulomas [16]. Dexamethasone is a corticosteroid medication used as a primary option in the treatment of granulomas [89]. This evidence reinforces the anti-inflammatory potential of bioactive compounds from kefir.

Therefore, in general, bioactive agents inhibited the expression of proinflammatory cytokines and the activation of the CCL20 promoter for in vitro inflammatory models with Caco-2 cells. In in vivo colitis models, bioactive compounds reduced weight loss, atrophy, and colon histological damage.

The compounds displayed anti-inflammatory action mechanisms by inhibiting the NF-κB pathway in the Caco-2 cells and the colon mucosa due to the expression of the IkBα inhibitor [50, 53, 56]. In addition, bioactive agents promoted the integrity of the intestinal barrier, increasing the expression of occludin, ZO-1, and claudin-1 occlusion proteins [50]. Additional anti-inflammatory mechanisms proposed for EPS were nitric oxide radical scavenging ability [54] and inhibition of hyaluronidase activity in cell-free in vitro systems [55]. Hydrolysis of the extracellular matrix by hyaluronidase releases compounds, like hyaluronan,
throughout inflammatory pathologies [90]. For extracellular vesicles, blocking myeloperoxidase activation in the mouse plasma has also been reported [53]. Oxidative stress in inflammatory bowel disease activates inflammatory cells, such as neutrophils, whose myeloperoxidase catalyzes the production of reactive oxygen species [91]. In this scenario, extracellular vesicles were as effective as the prednisolone drug in inhibiting myeloperoxidase [53]. Thus, the evidence suggests that bioactive compounds from kefir may play a decisive anti-inflammatory role.

However, EPS, including kefiran, can also have the opposite effect, acting as immunostimulants, in cases where there is no inflammatory insult (Table 2); this role was also corroborated in an in vivo model [58]. Their precursors in milk were glucose and galactose [51, 52]. In a minority way, bioactive peptides have also been reported as immunostimulants [57]. The Lactobacillus genus was relevant to produce these immunostimulants, especially the L. helveticus, L. pentosus, and L. kefiranofaciens species.

For EPS, although the intervention time has been similar for both a pro- and anti-inflammatory effect assay, the EPS concentration employed was dramatically higher; in vitro, the concentration for immunostimulating varied from 50 to 5000 μg/mL [4, 46, 51], while for inhibition, it reached the maximum of 100 μg/mL [50]. In vivo, 100 mg/kg bw was administered orally for immunostimulating [58], while to inhibit the immune response, the concentration ranged from 0.03 to 3 mg/kg bw [50]. This fact suggests that the concentration of EPS is a significant factor in determining the role that it will play on the immune system. In line, EPS has been reported to stimulate or inhibit the secretion of TNFα, IL-10, and IL-6 by in vitro murine macrophages, depending on the concentration tested [51, 52]. Thus, it appears that EPS can act by different cell signaling pathways, according to its concentration. However, the immunostimulatory mechanisms of action still need to be studied.

In vitro, the immunostimulatory role of EPS and bioactive peptides has been demonstrated in the macrophage’s cell line and primary culture, in addition to human peripheral blood mononuclear cells (PBMCs) (Table 2). R-5-EPS and R-17-EPS at 50-400 μg/mL stimulated proliferation, phagocytosis, phosphatase activity, IL-6 secretion, and NO production by RAW264.7 murine macrophage cells. Still, in the concentration range of 100 to 200 μg/mL, they stimulated the secretion of TNFα, IL-1β, and IL-10. EPSs were as efficient as lipopolysaccharides in promoting cell proliferation, phagocytosis, and cytokine secretion by macrophages [51, 52]. Kefiran at 1000 to 5000 μg/mL increased IL-6 secretion, and concentrations from 2000 to 4000 μg/mL stimulated cell proliferation of human PBMC culture by up to 200% after 24 h [46]. Bioactive peptide from L. kefiranofaciens, turn on, improved secretion of TNFα, IL-1β, IL-6, and IL-12 by 1000, 700, 1300, and 3000% by murine peritoneal macrophage culture. However, peptides from different microbial strains showed differences in immunostimulatory capacity [57], suggesting that the functional potential of the peptide is strain-dependent. In addition, bioactive peptide acted via the TLR2 receptor [57]; Toll-like receptor 2 enables macrophages to recognize microbial ligands, thereby promoting inflammation [92].

Consistently, oral administration of kefiran (100 mg/kg bw) to healthy mice for up to 7 days enhanced IgA, IL-10, IL-6, and IL-12 in the mucosa of the small intestine, as well as IL-4 and IL-12 in the fluid of the small intestine. In serum, kefiran increased IL-4, IL-6, IL-10, and IFN. However, broader immunostimulation occurred in the large intestine, increasing IgA, IgG, IL-4, IL-10, IL-6, INF, and TNF content. The most evident stimulatory activity in the large intestine has been attributed to the kefiran fermentation by intestinal microbiota [58]. Therefore, it appears that bioactivity may vary according to the biochemical transformations that these molecules undergo throughout the digestive process.

Finally, it is essential to highlight that immune stimulation can be interesting for a better prognosis of infectious conditions [93] and stimulating immunoglobulin production after vaccination [94]. Thus, the concentration and environmental context (presence or absence of inflammatory insult) are relevant factors to be considered according to the purpose of administering the bioactive compound.

Meta-analysis results corroborated the benefits of kefir bioactive compounds on immune modulation since the findings indicated that treatments had significant immune-modulatory activity compared to control (Supplementary Figure S4). The estimated (SMD) was (SMD (-1.17) (95% CI: -1.47—-0.87, and P ≤.001)). Heterogeneity was statistically significant moderate for this analysis (I² = 67%, P ≤ .001).

### 3.4.5. Anticancer Effect.

Cancer is a term that encompasses more than 100 different types of malignancies that have in typical disordered cell growth, which can metastasize [95]. However, although human in vitro models have reported anticancer effects of bioactive compounds from kefir on breast, colon, cervical and hepatocellular cancers, the lack of in vivo studies limits the understanding of the extent of their anticancer effect in organisms. Among the bioactive ones, EPS, including kefiran, had a broader impact, covering different types of cancer: breast, colon, cervical, and hepatocellular cancers (Table 2). The main precursors of EPS in the milk were glucose and galactose [47]. The Lactobacillus genus seemed relevant for EPS production with an anticancer effect on kefir (Table 2).

Kefiran reduced up to 45% of MCF7 breast cancer cell viability after 48 h of intervention, losing effect under the highest tested concentration of 4 mg/mL. However, efficiency decreased to 15.6% after 72 h, without effect at the lowest tested concentration of 0.5 mg/mL [46]. For HepG2 hepatocellular carcinoma cells, kefiran reduced their viability by up to 82% from the minimum concentration of 250 μg/mL. In contrast, for HeLa cervical carcinoma cells, kefiran reduced the viability by up to 72% in a dose-dependent manner [48]. Similarly, EPS MRS101 presented a dose-dependent effect on the viability of HT-29 colon cancer cells, reducing the number of viable cells by up to 55.9% after 24 h [47]. Therefore, the EPS concentration and the intervention time seem to be decisive for obtaining or not the anticarcinogenic effect. However, it is essential to note that developmental toxicity was observed in zebrafish embryos for kefiran concentrations above 100 μg/mL so that kefiran at 1000 μg/mL reaches 80% mortality [48].
In vivo, 10^{-3} to 3 \mu g/mL of EPS showed no toxicity on typical Vero cell culture [55]. Therefore, EPS can affect the growth of normal tissues depending on the concentration used, so this factor should be considered in future clinical applications.

The proposed mechanism of action for EPS was the upregulation of the apoptotic genes Cyto-c (cytochrome c), BAD (BCL2-associated agonist of cell death), BAX (BCL2-associated X protein), and caspases 3, 8, and 9; the increase in the expression of these genes ranged from 15 to 120%. In contrast, EPS downregulated by 70% the BCL2 gene, which is involved with the oxidative stability of the mitochondria [47]. Such changes in gene expression may be related to the adverse effects on the morphology of cancer cells. Loss of adherence capacity and formation of intracellular vacuoles were the more common changes resulting in cell death [48].

On the other hand, bioactive peptides have been reported only in an estrogen-sensitive breast cancer model. In addition, they showed a longer intervention time than other bioactive compounds described (Table 2). However, peptides appear to have lower toxicity as an advantage to EPS since peptides from kefir did not exert an antiproliferative effect on normal human mammary epithelial cells at doses of 0.31 to 10% (v/v). On the other hand, on those exact dosages, peptides reduced dose-dependent manner by up to 88% the MCF7-E3 human breast cancer estrogen-sensitive cell number [15], which indicates the specificity of this bioactive compound. Still, yogurt extracts showed dramatically lower efficiency than kefir extracts, in addition to presenting toxicity on normal human epithelial cells from a 5% (v/v) concentration. Nonfermented milk, unlike, had a negative effect, stimulating the proliferation of MCF7-E3 cancer cells [15]. These findings corroborate the anticarcinogenic specificity of peptides from kefir.

Although the anticancer effect of organic acids has not been directly tested, lactic and acetic acids present in kefir reduced fecal water-induced-DNA damage in HT-29 cells. Cultivation with fecal water for 30 min increased by 36% the DNA damage in HT-29 cells, being this effect more toxic than that caused by hydrogen peroxide [49]. However, fecal water-induced-DNA damage was inhibited with kefir supernatant by 20%. Thus, organic acids can have a preventive effect against colon cancer, attributed to their antioxidant activity. Inline, kefir presented antioxidant capacity (Trolox equivalent) 78.6% greater than unfermented milk [49], corroborating the role of organic acids produced during fermentation in protecting DNA.

Finally, the HT-29 colon cancer cell line [47, 49] appeared to be more sensitive to EPS than the MCF7 breast cancer cell line [46]. For the latter, the concentration reported for the assay was ten times greater (Table 2). Thus, sensitivity to the bioactive compounds from kefir appears to be dependent on cell type.

Validating our findings, treatments with bioactive compounds presented a significant anticarcinogenic effect, as the estimated (SMD) for overall anticancer effect was SMD (-2.44) (95% CI: -3.41--1.47, \( P \leq .001 \)) (Supplementary Figure S5). The data were homogeneous (\( I^2 = 46\% \), \( P \leq .0006 \)), which means good consistency among studies.

3.4.6. Plasma Glucose. Diabetes mellitus is a chronic glucose metabolism disorder with severe clinical consequences, such as retinopathy, nephropathy, and stroke [96]. Type 2 diabetes mellitus is a metabolic disorder marked by the rise in blood glucose due to a decrease in insulin secretion by pancreatic β-cells and insulin resistance. Additionally, the increase in the prevalence of diabetes mellitus worldwide in recent decades is associated with the rise in the prevalence of obesity in the population [96].

In this scenario, bioactive compounds in kefir were tested on glucose metabolism in obesity and diabetes murine models in vivo (Table 2). Oral administration (10 mL/kg bw) of a mixture of EPS-producer Leuconostoc mesenteroides LMDH4 and Lactobacillus kefiri LKDHS during eight weeks did not affect the plasma glucose level in diet-induced obese mice. However, this treatment effectively reduced adipocyte tissue weight by 36%, in addition to downregulating the pro-inflammatory and fatty acid synthesis gene expression in the adipocytes [76]. This fact indicates that the regulation of fatty acid metabolism in adipose tissue is not a determining factor in promoting a significant change in plasma glucose.

In contrast, administration of a mixture of 5 to 20 mL of kefir with black rice extract—1:1/kg bw—during four weeks enhanced by up to 199% and 2330% of the Langerhans islet in the pancreas and insulin-positive β-cells, respectively, in diabetic rats. The concentration from 10 mL/kg bw completely reversed the pancreatic damage induced by STZ-NA (Streptozotocin-nicotinamide), achieving a similar effect to the glibenclamide [78]. It is an antidiabetic drug of the second-generation sulfonylureas class that reduces blood glucose by increasing insulin secretion from pancreatic β-cells [97]. The effect was attributed to the proton-radical scavenging activity from alcohol and phenolic compounds present in the beverage [78]. This finding demonstrates that the antioxidative capacity must be a significant factor in promoting the homeostasis of insulin production by the pancreas. However, as the study did not test a formulation without adding black rice extract, it is impossible to determine how much of this positive effect on β-cells can be attributed to the kefir alone. Indeed, the addition of black rice extract increased by 56.8% the antioxidant capacity of the beverage compared to the kefir alone, as measured by DPPH [78].

Therefore, the current findings in the literature on the effect of bioactive compounds of kefir on glucose metabolism are inconclusive, so further preclinical studies with pure kefir drink or with bioactive compounds isolated from it are urgently needed.

3.4.7. Effect on Serum Cholesterol and Accumulation of Fat in the Adipose Tissue. Cardiovascular disease (CVD) is one of the major leading causes of morbidity and mortality worldwide. However, deaths by CVD are attributable to manageable risk factors, the main ones being high total serum cholesterol, high blood pressure, and smoking [98]. In addition, hypercholesterolemia is one of the risk conditions related to obesity [99]. In this scenario, reducing total serum cholesterol and fat accumulation in adipocytes is one of the strategies used to prevent CVD. However, pharmacological
drugs to treat obesity reportedly cause several side effects related to blood pressure, hepatic failure, pancreatitis, and headaches [100]. Therefore, research on natural compounds for the treatment of obesity has been encouraged.

Among the bioactive compounds from kefir, only EPS has been associated with lowering adipocyte fat and reducing in vitro cholesterol. *Lactococcus lactis* WH-C1, *Lactobacillus kefiri*, and *Leuconostoc mesenteroides* were the microorganisms identified as producers of these EPSs in the kefir [77]. However, the lack of investigation of their precursors in the milk shows a gap in the literature (Table 2).

EPS-producer *Lactococcus lactis* WH-C1 (4%, v/v) isolated from Tiber kefir grain could remove up to 31.23% of cholesterol from culture medium, demonstrating a potential hypcholesterolemic property in vitro [77]. In contrast, EPS was ineffective on an in vivo experimental model; supplementation for eight weeks with a mixture of EPS-producer heat-killed lactic acid bacteria (HLAB) isolated from kefir did not change the lipid profile in obese mice. Thus, serum HDL, LDL, total cholesterol, and triglycerides were not affected in diet-induced obese mice [76]. The lack of effect on serum cholesterol indicates that the concentration of EPS-producing microorganisms employed (1.1 × 10^10 CFU/mL) may have been insufficient to achieve significant changes in the cholesterol level in vivo. It must be taken into account that microorganisms became unable to continue the EPS production when they died from heating. Indeed, the greater the growth of the EPS-producing microorganism, the greater the cholesterol removal rate from the medium was demonstrated in vitro [77].

Similarly, kefir supplementation, which did not lead to a modulation of gut microbiota, is associated with low propionic acid production in the colon, which is insufficient to promote changes in the serum cholesterol level [101]. Also, the diet's inclusion of extract rich in polyphenol (wine grape seed flour -2.5%, v/v) did not alter the serum cholesterol levels [76]. Thus, antioxidative capacity may not be a significant factor in reducing blood cholesterol levels.

On the other hand, EPS ability to reduce the fat accumulation in the adipocytes was confirmed in vitro and in vivo animal models (Table 2). EPS isolated from strains of *Lactobacillus kefiri* and *Leuconostoc mesenteroides* showed inhibition (up to 28%) of lipid accumulation in 3T3-L1 adipocytes in vitro; this inhibition, in general, occurred in a dose-dependent manner [76]. In addition, the minimum concentration of EPS to obtain the effect appeared to be strain-dependent since only EPS from *L. mesenteroides* LMDH4 presented an effect at 0.01 mg/mL. At the same time, those from *L. kefiri* LKD3H and *L. mesenteroides* LMDH6 affected the fat accumulation only at the highest concentration tested (0.2 mg/mL). In contrast, EPS from *L. mesenteroides* LMDH8 and LMDH9 did not act even at the highest concentration tried (Table 2). This finding implies that the functional potential of EPS on fat accumulation varies according to its microbial origin.

About in vivo animal experiment, a diet supplemented with EPS-producer HLAB during eight weeks reduced by 36% the adipose tissue weight in C57BL/6 mice fed a high-fat and high-fructose diet [76]. This way, it suggests that EPS from kefir's microorganisms can be a functional ingredient capable of being used in obesity cases. EPS performance occurred through action on adipose tissue; expression of Wdfc21 and *Hp* proinflammatory genes was lowered by 56% and 57%, respectively, in the adipose tissue compared to the control group. Also, the expression of genes related to the synthesis of fatty acids (*Fabp4* and *Fsnn*) was downregulated by 55% and 43%, respectively, in the adipose tissue of the HLAB group. *Fabp4* encodes fatty acid-binding protein 4 (*Fabp4*), while *Fsnn* encodes fatty acid synthase. It demonstrates that EPS has roles in anti-inflammation and inhibiting the fatty acid synthesis in adipocytes. However, these effects on the Wdfc21, *Hp*, *Fabp4*, and *Fsnn* genes did not result in serum cholesterol changes, as its level has not been altered by treatment with HLAB.

Interestingly, supplementation of the diet with HLAB in conjunction with wine grape seed flour (2.5%), which is rich in polyphenol, potentiated the effect of reducing fat accumulation by 25% [76]. Therefore, antioxidant activity may be a relevant factor for reducing fat accumulation and can enhance the impact of EPS on adipocytes. Consequently, the synergistic treatment was the only one capable of significantly reducing the serum triglyceride.

### 3.4.8. Antihypertensive Effect

Hypertension is a chronic disease that leads to an increase in blood pressure [102]. Angiotensin-converting enzyme (ACE) is a key component of the renin-angiotensin system as part of the homeostatic mechanism to maintain adequate blood pressure levels in mammals. Conversion of ACE 1 to ACE 2 (an enzyme with a vasoconstrictor effect) is a common mechanism to regulate blood pressure [103]. But in abnormal conditions, this constriction can cause high blood pressure and increase the work required for the heart to pump blood into the body's main arteries [104]. In this way, inhibition in the conversion of ACE 1 to ACE 2 plays a role in managing hypertension.

As the systematic review selected only one article, it was the major limitation to a consistent understanding of the effect of bioactive compounds from kefir on blood pressure. Still, this study did not investigate the microorganism that produces the bioactive compound, its mechanism of action, nor the precursor of this bioactive compound in milk. In addition, the model studied was in situ. The absence of an investigation in vivo limits the understanding of the functional potential of bioactive compounds from kefir on blood pressure in physiological systems (Table 2).

In *in situ*, the ACE activity was reduced by 98.4% in the milk after fermentation with kefir grains for 24 h. The effect observed was attributed to bioactive peptides released by kefir’s microorganisms during the fermentation [14]. It suggests that bioactive peptides from kefir can have the potential to be used in the treatment of hypertension; however, further investigations are urgently needed to reach more consistent conclusions in the future.

### 3.4.9. Antioxidant Effect in Aging Models Related to Neurodegenerative Diseases

Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis are neurodegenerative diseases characterized by progressive loss of neuron cells, detriment of motor or cognitive functions, and accumulation of abnormal protein aggregates [105].
Aging is the primary risk factor for most neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. One in 10 individuals aged ≥65 has Alzheimer’s disease, and the prevalence of the disease continues to increase as age advances [106]. Mitochondrial dysfunction and consequent oxidative stress during aging are well-established factors that significantly influence the progress of neurodegenerative diseases [106]. The reactive oxygen species (ROS) production in aged mitochondria increases, the membrane potential becomes smaller, the ATP synthesis reduces, and the activity of respiratory enzyme complexes declines.

Consequently, oxidation and aggregation of proteins occur, in addition to the oxidation of mitochondrial DNA, which starts to present mutations and deletions [105]. Few or no effective treatments for age-related neurodegenerative diseases are available, so they tend to progress irreversibly. In this context, stem cell therapy is one of the alternative methods studied for the treatment of neurodegenerative diseases to regenerate the neuronal population [107].

The present systematic review selected only two properly controlled studies testing bioactive compounds from kefir as a therapeutic strategy in neurodegenerative diseases. In both, the potential of EPS was assessed (Table 2). The effect of kefiran on the proliferation of neural stem cell culture (PC12 cell culture) was investigated by Jenab et al. [46] for 5 and 10% kefiran concentrations associated with pure poly-acrylonitrile (PAN) to form nanofibers. When comparing with the control (PAN alone), however, both kefiran concentrations tested reduced up to 26.7% of the PC12 viability after one-day incubation, showing no significant effect after two days. On the fourth and sixth days, 10% kefiran reduced by 15.4% and 21.2%, respectively, the viability of the PC12 cell line. Thus, kefiran was not a suitable compound for promoting neuronal regeneration; unlike, it showed toxicity from 10% concentration.

On the other hand, oral administration of EPS (20 mL EPS solution/kg bw) during 12 weeks had a beneficial effect on the aging mouse model induced with D-galactose since EPS could mitigate the resulting oxidative stress. At a low dose (1 mg/mL), EPS enhanced by 27.7% the total antioxidant capacity in the serum. However, in addition to increasing the total antioxidant capacity, EPS increased serum glutathione peroxidase, superoxide dismutase, and catalase by 21.55, 33.14, and 61.09%, respectively. A 49.6% reduction in serum malondialdehyde accompanied the increased activity of the antioxidant enzymes reported [83]. Malondialdehyde, in turn, has been proposed as a biological marker of the progression of neurodegenerative diseases, including Parkinson’s disease, amyotrophic lateral sclerosis, and Alzheimer’s disease. It is because the elevation of peripheral malondialdehyde levels occurs in these diseases [108]. Thus, the reduction of serum malondialdehyde suggests that EPS can mitigate the progression of neurodegenerative diseases.

Lactobacillus plantarum YW11 was identified as the EPS-producing microorganism with antioxidant activity (Table 2). The antioxidant effect of EPS at the peripheral level was attributed to its ability to modulate intestinal microbiota positively. This modulatory effect was associated with a reduction of oxidative stress in the intestinal tract; the decrease in NOx with a simultaneous increase in acetic and butyric acids in feces illustrates the potential of EPS in improving the oxidative conditions of the host’s intestinal tract (Figure 2). Interestingly, EPS was more efficient than ascorbic acid in reducing the level of NOx and just as efficient in raising the content of short-chain fatty acids in the intestine. The antioxidant capacity of EPS can be attributed to its scavenging ability on hydroxyl radicals, DPPH radicals, and superoxide anion, in addition to Fe²⁺ chelating ability [83].

Therefore, EPSs from kefir seem more promising in terms of preventive effects than for therapeutic purposes. Indeed, the aging mouse model exhibits similar characteristics to those presented in the early stage of neurodegenerative diseases, such as oxidative stress. Therefore, this model is well-established for studying the earliest neurodegenerative changes associated with these diseases [109]. However, human clinical trials and more preclinical assays must be performed to corroborate this hypothesis.

3.4.10. Effect on Osteoporosis. The systematic review here selected only 1 study on the effect of the bioactive compounds on osteoporosis [80]. However, the in vivo animal study did not investigate the microorganisms that produce the bioactive compound in kefir, nor its precursor in milk. The mechanisms of action have also not been described. Therefore, further studies are urgently needed better to understand the effect of kefiran bioactive compounds on osteoporosis.

The ovariectomized procedure in female mice resulted in osteoporosis associated with the fall of the estrogen hormone due to the removal of the ovaries. These are the main glands that produce estrogen, which caused an imbalance between osteoblastic and osteoclastic activities in the bone. Consequently, there was a reduction of approximately 16%, 70%, and 70% of the bone mineral density, trabecular bone volume, and trabecular number in mice. However, the supplementation with bioactive peptides from kefir (100 mg/kg body weight) to ovariectomized mice could inhibit bone loss. Thus, the peptides increased the bone mineral density, trabecular bone volume, trabecular number, and the mechanical properties of the elastic modulus and hardness of the bones by 41%, 264%, 235%, 42%, and 36%, respectively. Consequently, a reduction of 36.5% and 33% in the trabecular separation and nanoindentation areas on the femur was obtained. It is important to note that peptide supplementation could ultimately reverse the condition of osteoporosis since the bone mineral density, trabecular number, trabecular separation, elastic modulus, hardness, and nanoindentation areas were similar to those of the negative control (nonovariectomized female).

Administration of calcium carbonate, standard procedure for osteoporosis treatment, also could enhance the trabecular bone volume and trabecular number. However, these values were about 0.7 times lower than those obtained by supplementation with bioactive peptides, demonstrating the potential of the peptides from kefir as a therapeutic agent in osteoporosis. Finally, no significant difference in the effects of calcium and bioactive peptides’ combined action concerning isolated bioactive peptides revealed no synergism between these two treatments [80].
3.5. Do Bioactive Compounds from Artisanal and Industrial Kefir Differ in Terms of Their Functional Potential? Two groups were assessed for comparing artisanal (kefir grain) and industrial (starter culture) kefir trials regarding their functional properties (Figure 3). First, we target effects related to antibacterial/antifungal potential resulting in an estimated OR of 2.96 (95% CI: 0.87–10.05, \( P = 0.07 \)). Therefore, the type of kefir was not significantly associated with its antimicrobial potential. This result agrees with our findings (Table 2), which reported the organic acids (especially lactic acid) as one of the main responsible bioactive compounds for the antimicrobial effect in both types of kefir.

After aiming to evaluate artisanal and industrial kefir outcomes concerning antioxidant potential, another group analysis was carried out, resulting in an estimated OR of 8.56 (95% CI: 2.27–32.21, \( P \leq 0.001 \)). Therefore, the utilization of artisanal kefir may provide 756% higher chances of having antioxidant effects than kefir from the industrial process. As stated before, phenolic compounds were the bioactive compounds responsible for industrial kefir antioxidant activity. In contrast, artisanal kefir presented a greater diversity of bioactive antioxidant compounds; in addition to phenolic compounds, artisanal kefir also contained bioactive peptides and EPS, including kefiran (artisanal kefir-exclusive structure) (Table 2). Although the phenolic compounds in industrial kefir have reducing power, they were ineffective in terms of the radical scavenging ability [85], unlike the phenolics present in artisanal kefir [75]. These findings suggest a different profile of phenolic compounds between both kefirs that can affect the antioxidant potential. In addition, the greater diversity of bioactive compounds in artisanal kefir may have contributed to potentiate the antioxidant capacity of this type of kefir (Table 2).

The difference in the antioxidant potential may be related to the different microbial profiles between the types of kefir since the microorganisms reported as producers of the antioxidant compounds present in artisanal kefir [28, 73] are not commonly found in industrial kefir (Table 1). Indeed, artisanal kefir’s more diverse microbial profile has been suggested as responsible for granting better functional benefits than industrial kefir [20]. Consistently, as discussed earlier, we observed a dramatically greater fungal diversity in artisanal kefir. In addition, the bacterial composition between both kefirs presented particularities (Table 1). Therefore, the microbial profile of artisanal kefir seems to be related to producing a greater diversity of bioactive compounds with antioxidant potential.

However, it is essential to report that because artisanal kefir is often primarily selected for kefir studies, only a few studies reporting industrial kefir findings were included in the meta-analysis, which was a limiting factor for comparison between kefir types.

4. Conclusion and Prospect

This review highlights the potential of bioactive compounds from kefir as preventive and therapeutic agents. There is an abundance of studies addressing the health benefits of kefir administration. However, a literature limitation is uncontrolled experiments or not identifying the bioactive compounds responsible for the observed health benefits. In addition, the relative scarcity of studies investigating the bioactive compounds-producer microorganisms and their substrates in milk constitutes a gap in the literature. The meta-analysis corroborated the antimicrobial, anticancer, and immune-modulatory activities. Kefiran and lactic acid were the main components with global antimicrobial action. However, kefiran presented a concentration threshold from which it exerted a bactericidal rather than a bacteriostatic effect. At the same time, lactic acid inhibited the germination of bacterial spores in a dose-dependent manner. Still, EPSs, including kefiran, were primarily responsible for the activity against colon and breast cancer. Nevertheless, the EPS concentration and intervention time were decisive for obtaining or not the anticancer effect, with EPS presenting a dose-dependent inhibitory effect for cervical carcinoma and colon cancer.

Regarding the anti-inflammatory effect, EPS, extracellular vesicles, and lactate were the main bioactive agents involved. However, EPS can also have an immunostimulatory effect, depending on its concentration and environmental conditions.
Finally, artisanal and industrial kefir is effective, and further studies are needed for consistent conclusions.

Bioactive compounds on plasma glucose level, neurodegenerative disease, associated with different potential depending on the health activity and gut modulation have shown a trend that favors fermentation by different bioactive compounds were diverse, indicating that they can act by different signaling pathways. Although antioxidant activity and gut modulation have shown a trend that favors kefir efficacy, they did not reach statistical significance, possibly due to the high heterogeneity of the data. Thus, standardization of the methodologies used to evaluate these effects will help compare different studies in the future. Bioactive compounds on plasma glucose level, neurodegenerative disease, lipid profile, blood pressure, and osteoporosis were inconclusive, and further studies are needed for consistent conclusions. Finally, artisanal and industrial kefir can have different functional potential depending on the health effect, which can be associated with differences in the microbial composition between both types of kefir.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (process nos. E-26/201.185/2014, E-26/010.001.911/2015, E-26/202.034/2017, E-26/200.060/2020, and E-26/200.542/2020, FAPERJ, Brazil), Conselho Nacional de Desenvolvimento Científico e Tecnológico (process nos. 311422/2016-0, 439731/2016-0, and 150200/2017-0 CNPq, Brazil), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (process no. 125, CAPES/Embrapa 2014, CAPES, Brazil) for the financial support.

Supplementary Materials

Figure S1: forest plot of the standardized mean difference (SMD) and 95% confidence intervals for studies concerning the presence or lack of antimicrobial effect of kefir bioactive compounds compared to control treatments; Figure S2: forest plot of the standardized mean difference (SMD) and 95% confidence intervals for studies concerning the presence or lack of antioxidant effect of kefir bioactive compounds compared to control treatments; Figure S3: forest plot of the standardized mean difference (SMD) and 95% confidence intervals for studies concerning the presence or lack of gut microbiota modulation effect of kefir bioactive compounds compared to control treatments; Figure S4: forest plot of the standardized mean difference (SMD) and 95% confidence intervals for studies concerning the presence or lack of immune modulation effect of kefir bioactive compounds compared to control treatments; Figure S5: forest plot of the standardized mean difference (SMD) and 95% confidence intervals for studies concerning the presence or lack of anticancer effect of kefir bioactive compounds compared to control treatments. (Supplementary Materials)

References

[1] M. A. Azhar and M. S. A. Munaim, “Identification and evaluation of probiotic potential in yeast strains found in kefir drink samples from Malaysia,” International Journal of Food Engineering, vol. 15, no. 7, pp. 1–11, 2019.

[2] Z. Kesmen and N. Kacmaz, “Determination of lactic microflora of kefir grains and kefir beverage by using culture-dependent and culture-independent methods,” Journal of Food Science, vol. 76, no. 5, pp. M276–M283, 2011.

[3] O. Gul, I. Atalar, M. Mortas, and M. Dervisoglu, “Rheological, textural, colour and sensorial properties of kefir produced with buffalo milk using kefir grains and starter culture: a comparison with cows’ milk kefir,” International Journal of Dairy Technology, vol. 71, pp. 73–80, 2018.

[4] I. Yilmaz, M. E. Dolar, and H. Ozgunar, “Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial,” Turkish Journal of Gastroenterology, vol. 30, no. 3, pp. 242–253, 2019.

[5] K. V. O’Brien, L. K. Stewart, L. A. Forney, K. J. Aryana, W. Prinyawiwatkul, and C. A. Boeneke, “The effects of post-exercise consumption of a kefir beverage on performance and recovery during intensive endurance training,” Journal of Dairy Science, vol. 98, no. 11, pp. 7446–7449, 2015.

[6] M. Sharifi, A. Moridnia, D. Mortazavi, M. Salehi, M. Bagheri, and A. Sheikhi, “Kefir: a powerful probiotics with anticancer properties,” Medical Oncology, vol. 34, no. 11, p. 183, 2017.

[7] N. Alihosseini, S. A. Moahboob, N. Farrin, M. Mobasser, A. Taghizadeh, and A. R. Ostadrahimi, "Effect of probiotic fermented milk (kefir) on serum level of insulin and homocysteine in type 2 diabetes patients," Acta Endocrinologica (Bucharest), vol. 13, no. 4, pp. 431–436, 2017.

[8] Y. Fathi, N. Ghodrati, M.-J. Zibaenezhad, and S. Faghih, “Kefir drink causes a significant yet similar improvement in serum lipid profile, compared with low-fat milk, in a dairy-rich diet in overweight or obese premenopausal women: a randomized controlled trial,” Journal of Clinical Lipidology, vol. 11, no. 1, pp. 136–146, 2017.

[9] M.-Y. Tu, H.-L. Chen, Y.-T. Tung, C.-C. Kao, F.-C. Hu, and C.-M. Chen, "Short-term effects of kefir-fermented milk consumption on bone mineral density and bone metabolism in a randomized clinical trial of osteoporotic patients," PLoS One, vol. 10, no. 12, 2015.

[10] A. M. M. Ton, B. P. Campagnaro, G. A. Alves et al., “Oxidative stress and dementia in Alzheimer’s patients: effects of synbiotic supplementation,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 2638703, 14 pages, 2020.

[11] H. Mert, H. Yilmaz, K. Irak, S. Yıldırım, and N. Mert, “Investigation of the protective effect of kefir against isoproterenol induced myocardial infarction in rats,” Korean Journal for
Food Science of Animal Resources, vol. 38, no. 2, pp. 259–272, 2018.

[12] Y.-J. Hsu, W.-C. Huang, J.-S. Lin et al., “Kefir supplementation modifies gut microbiota composition, reduces physical fatigue, and improves exercise performance in mice,” Nutrients, vol. 10, no. 7, p. 862, 2018.

[13] A. A. Bengoa, M. G. Llamas, C. Iraporda, M. T. Dueñas, A. G. Abraham, and G. L. Garrote, “Impact of growth temperature on exopolysaccharide production and probiotic properties of Lactobacillus paracasei strains isolated from kefir grains,” Food Microbiology, vol. 69, pp. 212–218, 2018.

[14] R. R. Gamba, S. Yamamoto, M. Abdel-Hamid et al., “Chemical, microbiological, and functional characterization of kefir produced from cow’s milk and soy milk,” International Journal of Microbiology, vol. 2020, Article ID 7019286, 11 pages, 2020.

[15] C. Chen, H. M. Chan, and S. Kubow, “In vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells,” Journal of Medicinal Food, vol. 10, no. 3, pp. 416–422, 2007.

[16] K. L. Rodrigues, J. C. T. Carvalho, and J. M. Schnedorf, “Anti-inflammatory properties of kefir and its polysaccharide extract,” Inflammopharmacology, vol. 13, no. 5–6, pp. 485–492, 2005.

[17] S. Yesillik, N. Yildirim, A. Dikici, A. Yildiz, and S. Yesillik, “Antibacterial effects of some fermented commercial and homemade dairy products and 0.9% lactic acid against selected foodborne pathogens,” Asian Journal of Animal and Veterinary Advances, vol. 6, no. 2, pp. 189–195, 2011.

[18] C. Garofalo, I. Ferrocino, A. Reale et al., “Study of kefir drinks produced by backslapping method using kefir grains from Bosnia and Herzegovina: microbial dynamics and volatilome profile,” Food Research International, vol. 137, p. 109369, 2020.

[19] A. Sindhi, M. B. Badsha, and G. Unlu, “Bacterial populations in international artisanal kefirs,” Microorganisms, vol. 8, no. 9, p. 1318, 2020.

[20] F. P. Rattray and M. J. O’Connell, “Fermented milks|kefir,” in Encyclopedia of Dairy Sciences, pp. 518–524, Elsevier, 2011.

[21] B. C. T. Bourrie, P. D. Cotter, and B. P. Willing, “Traditional kefir reduces weight gain and improves plasma and liver lipid profiles more successfully than a commercial equivalent in a mouse model of obesity,” Journal of Functional Foods, vol. 46, pp. 29–37, 2018.

[22] A. Quirós, B. Hernández-Ledesma, M. Ramos, L. Amigo, and I. Recio, “Angiotensin-converting enzyme inhibitory activity of peptides derived from caprine kefir,” Journal of Dairy Science, vol. 88, no. 10, pp. 3480–3487, 2005.

[23] J. Ebner, A. Asçi Arslan, M. Fedorova, R. Hoffmann, A. Küçükgüzetin, and M. Pischetsrieder, “Peptide profiling of bovine kefir reveals 236 unique peptides released from caseins during its production by starter culture or kefir grains,” Journal of Proteomics, vol. 117, pp. 41–57, 2015.

[24] S. Sarkar, “Potential of kefir as a dietary beverage – a review,” British Food Journal, vol. 109, no. 4, pp. 280–290, 2007.

[25] Z. Ahmed, Y. Wang, A. Ahmad et al., “Kefir and health: a contemporary perspective,” Critical Reviews in Food Science and Nutrition, vol. 53, no. 5, pp. 422–434, 2013.

[26] B. C. T. Bourrie, C. Richard, and B. P. Willing, “Kefir in the prevention and treatment of obesity and metabolic disorders,” Current Nutrition Reports, vol. 9, no. 3, pp. 184–192, 2020.

[27] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” BMJ, vol. 327, no. 7414, pp. 557–560, 2003.

[28] Z. Chen, J. Shi, X. Yang, Y. Liu, B. Nan, and Z. Wang, “Isolation of exopolysaccharide-producing bacteria and yeasts from Tibetan kefir and characterisation of the exopolysaccharides,” International Journal of Dairy Technology, vol. 69, no. 3, pp. 410–417, 2016.

[29] N. Korsak, B. Taminiau, M. Leclercq et al., “Short communication: evaluation of the microbiota of kefir samples using metagenetic analysis targeting the 16S and 26S ribosomal DNA fragments,” Journal of Dairy Science, vol. 98, no. 6, pp. 3684–3689, 2015.

[30] A. Jankowska, A. Reps, A. Proszek, M. Krasowska, S. Porowski, and J. Szczep, “Influence of high pressure on some biochemical properties of kefir microflora (effect of HPP on kefir microflora),” High Pressure Research, vol. 23, no. 1–2, pp. 87–92, 2003.

[31] E. J. Kakisu, A. G. Abraham, P. F. Pérez, and G. L. De Antoni, “Inhibition of Bacillus cereus in milk fermented with kefir grains,” Journal of Food Protection, vol. 70, no. 11, pp. 2613–2616, 2007.

[32] A. M. Leite, M. A. Miguel, R. S. Peixoto et al., “Probiotic potential of selected lactic acid bacteria strains isolated from Brazilian kefir grains,” Journal of Dairy Science, vol. 98, no. 6, pp. 3622–3632, 2015.

[33] A. J. Marsh, O. O’Sullivan, C. Hill, R. P. Ross, and P. D. Cotter, “Sequencing-based analysis of the bacterial and fungal composition of kefir grains and milks from multiple sources,” Plos One, vol. 8, no. 7, p. e69371, 2013.

[34] A. A. Kholkacheva, M. A. Egorova, A. N. Kalinina, and N. B. Gradova, “Trophic patterns of functioning and microbial profile of the evolutionally established associated kefir grains culture,” Microbiology, vol. 84, no. 4, pp. 561–569, 2015.

[35] A. M. Walsh, F. Crispie, K. Kilcawley et al., “Microbial succession and flavor production in the fermented dairy beverage kefir,” mSystems, vol. 1, no. 5, 2016.

[36] D. F. Zanirati, M. Abatemarco, S. H. de Cicco Sandes, J. R. Nicolí, A. C. Nunes, and E. Neumann, “Selection of lactic acid bacteria from Brazilian kefir grains for potential use as starter or probiotic cultures,” Anaerobe, vol. 32, pp. 70–76, 2015.

[37] P. G. de Almeida Brasil, J. Dutra Medeiros, A. Barbosa Ferreira Machado, M. Schuchter Ferreira, M. D. Gouveia, and P. S. W. Peluzio, and S. C. Potente Dutra Luquetti, “Microbial community dynamics of fermented kefir beverages changes over time,” International Journal of Dairy Technology, vol. 74, no. 2, pp. 324–331, 2021.

[38] C. P. Vieira, C. C. Cabral, B. R. da Costa Lima, V. M. Paschoalin, K. C. Leandro, and C. A. Conte-Junior, “Lactococcus lactis ssp. cremoris MR547, a potential probiotic strain isolated from kefir grains, increases cis-9, trans-11-CLA and PUFA contents in fermented milk,” Journal of Functional Foods, vol. 31, pp. 172–178, 2017.

[39] I. Mantzourani, P. Chondrou, C. Bontsidis et al., “Assessment of the probiotic potential of lactic acid bacteria isolated from kefir grains: evaluation of adhesion and antiproliferative properties in in vitro experimental systems,” Ann Microbiol, vol. 69, no. 7, pp. 751–763, 2019.

[40] A. Sindhi, M. Badsha, B. Nielsen, and G. Unlu, “Antimicrobial activity of six international artisanal kefirs against Bacillus cereus, Listeria monocytogenes, Salmonella enterica serovar...
Enteritidis, and Staphylococcus aureus," Microorganisms, vol. 8, p. 849, 2020.

[41] F. Serafini, F. Turroni, P. Ruas-Madiedo et al., "Kefir fermented milk and kefir grain promote growth of Bifidobacterium bifidum PRL2010 and modulate its gene expression," International Journal of Food Microbiology, vol. 178, pp. 50–59, 2014.

[42] F. S. Erdogan, S. Ozarslan, Z. B. Guzel-Seydim, and T. Kök Taş, "The effect of kefir grain from natural kefir grains on the intestinal microbial populations and antioxidant capacities of Balb/c mice," Food Research International, vol. 115, pp. 408–413, 2019.

[43] Y. Wang, J. Wang, Z. Ahmed, X. Bai, and J. Wang, "Complete genome sequence of Lactobacillus kefiroinfaciens ZW3," Journal of Bacteriology, vol. 193, no. 16, pp. 4280–4281, 2011.

[44] J.-Y. Hong, N.-K. Lee, S.-H. Yi, S.-P. Hong, and H.-D. Paik, "Short communication: physicochemical features and microbial community of milk kefir using a potential probiotic Saccharomyces cerevisiae KU200284," Journal of Dairy Science, vol. 102, no. 12, pp. 10845–10849, 2019.

[45] D.-H. Kim, H. Kim, and K.-H. Seo, "Microbial composition of Korean kefir and antimicrobial activity of Acetobacter fabarum DH1801," Journal of Food Safety, vol. 40, article e12728, 2020.

[46] A. Jenab, R. Roghanian, N. Ghorbani, K. Ghaedi, and G. Emtiazi, "The efficiency of electrosup PÁN/Kefiran nanofiber and kefir in mammalian cell culture: promotion of PC12 cell growth, anti-MCF7 breast cancer cells activities, and cytokine production of BM-MSC," International Journal of Nanomedicine, vol. 15, pp. 717–728, 2020.

[47] M. S. Rajoka, H. M. Mehwish, H. Fang et al., "Characterization and anti-tumor activity of exopolysaccharide produced by Lactobacillus kefiri isolated from Chinese kefir grains," Journal of Functional Foods, vol. 63, article 103588, 2019.

[48] E. EA and E. E. HA, "In vitro and in vivo biological screening of kefir polysaccharide produced by Lactobacillus kefiroinfaciens," Biomedical Research, vol. 28, no. 2, pp. 594–600, 2017.

[49] A. Grishina, I. Kulikova, L. Alieva, A. Dodson, I. Rowland, and J. Jin, "Antigenotoxic effect of kefir and ayan supernatants on feline water-induced DNA damage in human colon cells," Nutrition and Cancer, vol. 63, no. 1, pp. 73–79, 2011.

[50] E. Kang, H. I. Choi, S. W. Hong et al., "Extracellular vesicles derived from kefir grain Lactobacillus ameliorate intestinal inflammation via regulation of proinflammatory pathway and tight junction integrity," Biomedicine, vol. 8, no. 11, pp. 1–11, 2020.

[51] X. You, L. Yang, X. Zhao et al., "Isolation, purification, characterization and immunostimulatory activity of an exopolysaccharide produced by Lactobacillus pentosus LZ-R-17 isolated from Tibetan kefir," International Journal of Biological Macromolecules, vol. 158, pp. 408–419, 2020.

[52] X. You, Z. Li, K. Ma et al., "Structural characterization and immunomodulatory activity of an exopolysaccharide produced by Lactobacillus helveticus LZ-R-5," Carbohydrate Polymers, vol. 235, p. 115977, 2020.

[53] M. K. Boo, E. J. Park, S. Y. Ko, E. W. Choi, and S. Kim, "Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2,4,6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease," Journal of Dairy Science, vol. 101, no. 10, pp. 8662–8671, 2018.

[54] H. Radhouani, C. Gonçalves, F. R. Maia, J. M. Oliveira, and R. L. Reis, "Biological performance of a promising Kefiran-biopolymer with potential in regenerative medicine applications: a comparative study with hyaluronic acid," Journal of Materials Science: Materials in Medicine, vol. 29, no. 8, p. 124, 2018.

[55] M. R. M. Prado, C. Boller, R. G. M. Zibetti, D. de Souza, L. L. Pedroso, and C. R. Soccol, "Anti-inflammatory and angiogenic activity of polysaccharide extract obtained from Tibetan kefir," Microvascular Research, vol. 108, pp. 29–33, 2016.

[56] C. Irpolda, D. E. Rominan, M. Rumbo, G. L. Garrote, and A. G. Abraham, "The role of lactate on the immunomodulatory properties of the nonbacterial fraction of kefir," Food Research International, vol. 62, pp. 247–253, 2014.

[57] W. S. Hong, H. C. Chen, Y. P. Chen, and M. J. Chen, "Effects of kefir supernatant and lactic acid bacteria isolated from kefir grain on cytokine production by macrophage," International Dairy Journal, vol. 19, no. 4, pp. 244–251, 2009.

[58] G. Vinderola, G. Perdigón, J. Duarte, E. Farnworth, and C. Matar, "Effects of the oral administration of the exopolysaccharide produced by Lactobacillus kefiranfaciens on the gut mucosal immunity," Cytokine, vol. 36, no. 5–6, pp. 254–260, 2006.

[59] P. A. Bolla, P. Carasi, M. de los Angeles Serradell, and G. L. De Antoni, "Kefir-isolated Lactococcus lactis subsp. lactis inhibits the cytotoxic effect of Clostridium difficile in vitro," Journal of Dairy Research, vol. 80, pp. 96–102, 2013.

[60] S. S. S. Yirmibesoglu and B. E. Tefon Ozturk, "Comparing microbiological profiles, bioactivities, and physicochemical and sensory properties of donkey milk kefir and cow milk kefir," Turkish Journal of Veterinary and Animal Sciences, vol. 44, pp. 774–781, 2020.

[61] S.-M. Hasheminya and D. Dehghanya, "Novel ultrasound-assisted extraction of kefiran biomaterial, a prebiotic exopolysaccharide, and investigation of its physicochemical, antioxidant and antimicrobial properties," Materials Chemistry and Physics, vol. 243, article 122645, 2020.

[62] V. D. Marques, M. R. Franzolin, S. S. Sanabani et al., "A new class of antimicrobial molecules derived from kefir, effective against Pseudomonas aeruginosa and methicillin resistant Staphylococcus aureus (MRSA) strains," Scientific Reports, vol. 10, article 17434, 2020.

[63] X. Duan, S. Chen, S. Duan et al., "Antibiotic activities of the natural antimicrobial substance produced by Lactobacillus paracasei FX-6 against Pseudomonas putida," LWT, vol. 123, article 109096, 2020.

[64] M. D. de Lima, R. A. da Silva, M. F. da Silva et al., "Brazilian kefir-fermented sheep’s milk, a source of antimicrobial and antioxidant peptides," Probiotics and Antimicrobial Proteins, vol. 10, pp. 446–455, 2018.

[65] D. Jeong, D. H. Kim, L. B. Kang et al., "Characterization and antibacterial activity of a novel exopolysaccharide produced by Lactobacillus kefiranfaciens DN1 isolated from kefir," Food Control, vol. 78, pp. 436–442, 2017.

[66] C. Iraporda, M. A. Júnior, E. Neumann et al., "Biological activity of the non-microbial fraction of kefir: antagonism against intestinal pathogens," Journal of Dairy Research, vol. 84, pp. 339–345, 2017.

[67] L. M. Kumar, W. Z. Saad, R. Mohamad, and R. A. Rahim, "Influence of biofilm-forming lactic acid bacteria against methicillin-resistant Staphylococcus aureus (MRSA S547),"
Asian Pacific Journal of Tropical Biomedicine, vol. 7, pp. 1107–1115, 2017.

[68] J. Miao, G. Liu, C. Ke et al., “Inhibitory effects of a novel anti-microbial peptide from kefir against Escherichia coli,” Food Control, vol. 65, pp. 63–72, 2016.

[69] L. M. Blandón, G. A. Islan, G. R. Castro, M. D. Nosedo, V. Thomaz-Soccol, and C. R. Soccol, “Kefiran-alginate gel microspheres for oral delivery of ciprofloxacin,” Colloids and Surfaces B: Biointerfaces, vol. 145, pp. 706–715, 2016.

[70] A. Londero, M. A. León Peláez, G. Diosma, G. L. De Antoni, A. G. Abraham, and G. L. Garrote, “Fermented whey as poultry feed additive to prevent fungal contamination,” Journal of the Science of Food and Agriculture, vol. 94, pp. 3189–3194, 2014.

[71] A. A. Ismaiel, M. F. Ghaly, and A. K. El-Naggar, “Milk kefir: ultrastructure, antimicrobial activity and efficacy on aflatoxin B1 production by Aspergillus flavus,” Current Microbiology, vol. 62, pp. 1602–1609, 2011.

[72] M. A. Golowczyc, P. Mobili, G. L. Garrote, A. G. Abraham, and G. L. De Antoni, “Protective action of Lactobacillus kefir carrying S-layer protein against Salmonella enterica serovar Enteritidis,” International Journal of Food Microbiology, vol. 118, pp. 264–273, 2007.

[73] V. Luang-In and S. Deeseenthum, “Exopolysaccharide-producing isolates from Thai milk kefir and their antioxidant activities,” LWT, vol. 73, pp. 592–601, 2016.

[74] F. A. Fiorda, G. V. de Melo Pereira, V. Thomaz-Soccol, A. P. Medeiros, S. K. Rakshit, and C. R. Soccol, “Development of kefir-based probiotic beverages with DNA protection and antioxidant activities using soybean hydrolyzed extract, colostrum and honey,” LWT-Food Science and Technology, vol. 68, pp. 690–697, 2016.

[75] G. Satir and Z. B. Guzel-Seydim, “Influence of Kefir fermentation on the bioactive substances of different bread grain milks,” LWT-Food Science and Technology, vol. 63, pp. 852–858, 2015.

[76] K.-H. Seo, J. Jeong, and H. Kim, “Synergistic effects of heat-killed kefir paraprobiotics and flavonoid-rich prebiotics on western diet-induced obesity,” Nutrients, vol. 12, p. 2465, 2020.

[77] J. Wang, Z. Xing, W. Tang, Y. Zheng, and Y. Wang, “Isolation, identification, and potential probiotic characterization of one Lactococcus from Kefir grain,” Food Science and Biotechnology, vol. 24, no. 5, pp. 1775–1780, 2015.

[78] A. Nurliyani, H. Sadewa, and Sunarti, “Kefir properties prepared with goat milk and black rice (Oryza sativa L.) extract and its influence on the improvement of pancreatic β-cells in diabetic rats,” Emirates Journal of Food and Agriculture, vol. 27, no. 10, pp. 727–735, 2015.

[79] A. A. Bengoa, C. Dardis, N. Gagliarini, G. L. Garrote, and A. G. Abraham, “Exopolysaccharides from Lactobacillus paracasei isolated from kefir as potential bioactive compounds for microbiota modulation,” Frontiers in Microbiology, vol. 11, 2020.

[80] M. Y. Tu, K. Y. Han, G. R. Chang et al., “Kefir peptides prevent estrogen deficiency-induced bone loss and modulate the structure of the gut microbiota in ovariectomized mice,” Nutrients, vol. 12, no. 11, p. 3432, 2020.

[81] Z. Xing, W. Tang, W. Geng, Y. Zheng, and Y. Wang, “In vitro and in vivo evaluation of the probiotic attributes of Lactobacillus kefiranofaciens XI.10 isolated from Tibetan kefir grain,” Applied Microbiology and Biotechnology, vol. 101, pp. 2467–2477, 2017.

[82] M. F. Hamet, M. Medrano, P. F. Pérez, and A. G. Abraham, “Oral administration of kefiran exerts a bifidogenic effect on BALB/c mice intestinal microbiota,” Beneficial Microbes, vol. 7, pp. 237–246, 2016.

[83] J. Zhang, X. Zhao, Y. Jiang et al., “Antioxidant status and gut microbiota change in an aging mouse model as influenced by exopolysaccharide produced by Lactobacillus plantarum WY11 isolated from Tibetan kefir,” Journal of Dairy Science, vol. 100, no. 8, pp. 6025–6041, 2017.

[84] Y. Liu and J. Shi, “Antioxidative nanomaterials and biomedical applications,” Nano Today, vol. 27, pp. 146–177, 2019.

[85] L. Yilmaz-Ersan, T. Ozcan, A. Akpinar-Bayizit, and S. Sahin, “Comparison of antioxidant capacity of cow and ewe milk kefirs,” Journal of Dairy Science, vol. 101, pp. 3788–3798, 2018.

[86] L. Moja, S. Danese, G. Fiorino, C. D. Giovane, and S. Bonovas, “Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn’s disease,” Alimentary Pharmacology & Therapeutics, vol. 41, no. 11, pp. 1055–1065, 2015.

[87] W. Ericson-Neilsen and A. D. Kaye, “Steroids: pharmacology, complications, and practice delivery issues,” The Ochsner Journal, vol. 14, no. 2, pp. 203–207, 2014.

[88] S. Narum, T. Westergren, and M. Klemm, “Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis,” BMJ Open, vol. 4, no. 5, article e004587, 2014.

[89] G. Godazandeh, L. Shojaee, R. Alizadeh-Navaei, and A. Hessami, “Corticosteroids in idiopathic granulomatous mastitis: a systematic review and meta-analysis,” Surgery Today, 2021.

[90] A. C. Petrey and C. A. de la Motte, “Hyaluronan, a crucial regulator of inflammation,” Frontiers in Immunology, vol. 5, 2014.

[91] B. Chami, N. J. J. Martin, J. M. Dennis, and P. K. Witting, “Myeloperoxidase in the inflamed colon: a novel target for treating inflammatory bowel disease,” Archives of biochemistry and biophysics, vol. 645, pp. 61–71, 2018.

[92] J. Hoppsätänder, A. Dembek, R. Linnenberger et al., “Toll-like receptor 2 release by macrophages: an anti-inflammatory program induced by glucocorticoids and lipopolysaccharide,” Frontiers in Immunology, vol. 10, 2019.

[93] A. R. Lomax and P. C. Calder, “Prebiotics, immune function, infection and inflammation: a review of the evidence,” British Journal of Nutrition, vol. 101, pp. 633–658, 2008.

[94] M. Bosch, “Lactobacillus plantarum cect315 y cect7316 esti-
mula la producción de inmunoglobulinas tras la vacunación contra la influenza en ancianos,” Nutricion Hospitalaria, vol. 27, no. 2, pp. 504–509, 2012.

[95] K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic syndrome and risk of cancer: a systematic review and meta-analysis,” Diabetes Care, vol. 35, no. 11, pp. 2402–2411, 2012.

[96] N. G. Forouhi and N. J. Wareham, “Epidemiology of diabetes,” Medicine, vol. 47, pp. 22–27, 2019.

[97] V. Rambiritch, B. Maharaj, and P. Naidoo, “Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study,” Clinical Pharmacology, vol. 6, pp. 63–69, 2014.
[98] G. A. Roth, S. D. Fihn, A. H. Mokdad, W. Aekplakorn, T. Hasegawa, and S. S. Lim, "High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries," *Bulletin of the World Health Organization*, vol. 89, no. 2, pp. 92–101, 2011.

[99] Y. H. Lee, S. G. Lee, M. H. Lee et al., "Serum cholesterol concentration and prevalence, awareness, treatment, and control of high low-density lipoprotein cholesterol in the Korea National Health and Nutrition Examination Surveys 2008-2010: Beyond the Tip of the Iceberg," *Journal of the American Heart Association*, vol. 3, no. 1, article e000650, 2014.

[100] S. Bersoux, T. H. Byun, S. S. Chaliki, and K. G. Poole, "Pharmacotherapy for obesity: what you need to know," *Cleveland Clinic journal of medicine*, vol. 84, no. 12, pp. 951–958, 2017.

[101] M.-P. St-Onge, E. R. Farnworth, T. Savard, D. Chabot, A. Mafu, and P. J. H. Jones, "Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]," *BMC Complementary and Alternative Medicine*, vol. 2, p. 1, 2002.

[102] P. K. Arora and A. Chauhan, "ACE inhibitors: a comprehensive review," *International Journal of Pharmaceutical Sciences and Research*, vol. 4, no. 2, p. 532, 2013.

[103] D. Coates, "The angiotensin converting enzyme (ACE)," *The International Journal of Biochemistry & Cell Biology*, vol. 35, pp. 769–773, 2003.

[104] N. K. Sweitzer, "What is an angiotensin converting enzyme inhibitor?," *Circulation*, vol. 108, 2003.

[105] G. Cenini, A. Lloret, and R. Cascella, "Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 2105607, 18 pages, 2019.

[106] Y. Hou, X. Dan, M. Babbar et al., "Ageing as a risk factor for neurodegenerative disease," *Nature Reviews Neurology*, vol. 15, no. 10, 2019.

[107] M. Acquarone, T. M. de Melo, F. Meireles et al., "Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson’s disease," *Frontiers in Cellular Neuroscience*, vol. 9, 2015.

[108] M. Dib, C. Garrel, A. Favier, V. Robin, and C. Desnuelle, "Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease?," *Journal of Neurology*, vol. 249, pp. 367–374, 2002.

[109] M. Pallas, A. Camins, M. A. Smith, G. Perry, H. Lee, and G. Casadesus, "From aging to Alzheimer’s disease: unveiling ‘the switch’ with the senescence-accelerated mouse model (SAMP8)," *Journal of Alzheimer’s Disease*, vol. 15, pp. 615–624, 2008.